

ACTHAR

Products Affected

- ACTHAR

PA Criteria	Criteria Details
Exclusion Criteria	Coverage is not provided for diagnostic procedure.
Required Medical Information	Diagnosis, prescriber or consulting physician specialty, previous medications tried and response
Age Restrictions	Infantile spasms- less than 2yo. Acute MS exac-adult
Prescriber Restrictions	Infantile spasms, prescr/consult w/neurolo/epileptologist.MS exacerbation, prescr/consult w/neuro/phys specializes MS.RA, JIA/JRA, AS, PsA, SLE, Systemic Dermatomyositis, prescr/consult w/rheum.Severe Erythema Multiforme, prescr/consult w/derm.Serum Sickness,prescr/consult w/allergist.Severe acute/chronic allergic/inflamm processes of eye and its adnexa, prescr/consult w/ ophthalmologist.Symptomatic Sarcoidosis, prescr/consult w/pulm/cardio.Nephrotic Syndrome, prescr/consult w/nephrologist.
Coverage Duration	All diagnoses-1 month
Other Criteria	For acute MS exacerbation, approve if Acthar is NOT being used as pulse therapy on a monthly basis. For all other FDA approved diagnoses (other than Infantile spasms or MS exacerbation), approve if the patient has tried a systemic corticosteroid for the current condition and patient has experienced a severe adverse effect or treatment failure with the corticosteroid (e.g., a psychotic reaction).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

ACTIMMUNE

Products Affected

- ACTIMMUNE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

ADEMPAS

Products Affected

- ADEMPAS

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	PAH and CTEPH- must be prescribed by or in consultation with a cardiologist or a pulmonologist.
Coverage Duration	1 year
Other Criteria	For PAH - must have PAH (WHO Group 1) and had a right heart catheterization to confirm the diagnosis of PAH (WHO Group 1).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

AIMOVIG

Products Affected

- AIMOVIG AUTOINJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	Combination therapy with Ajoovy, Vyepti or Emgality
Required Medical Information	Diagnosis, number of migraine headaches per month, prior therapies tried
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Approve if the patient meets the following criteria (A and B): A) Patient has greater than or equal to 4 migraine headache days per month (prior to initiating a migraine-preventative medication), AND B) Patient has tried at least two standard prophylactic pharmacologic therapies, at least one drug each from a different pharmacologic class (e.g., anticonvulsant, beta-blocker), and has had inadequate responses to those therapies or the patient has a contraindication to other prophylactic pharmacologic therapies according to the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

ALDURAZYME

Products Affected

- ALDURAZYME

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, genetic and lab test results
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders
Coverage Duration	1 year
Other Criteria	Approve if the patient has a laboratory test demonstrating deficient alpha-L-iduronidase activity in leukocytes, fibroblasts, plasma, or serum OR has a molecular genetic test demonstrating alpha-L-iduronidase gene mutation
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

ALOSETRON

Products Affected

- *alosetron*

PA Criteria	Criteria Details
Exclusion Criteria	Alosetron will not be approved for use in men, as safety and efficacy in men has not been established.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Alosetron is considered medically necessary for the treatment of severe IBS-D. At least one of the following must be present for diarrhea to be considered severe: frequent and severe abdominal pain or discomfort, frequent bowel urgency or fecal incontinence, and disability or restriction of daily activities due to IBS.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

AMPYRA

Products Affected

- *dalfampridine*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	MS. If prescribed by, or in consultation with, a neurologist or MS specialist.
Coverage Duration	Authorization will be for 1 year.
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

ANABOLIC STEROIDS

Products Affected

- ANADROL-50
- *oxandrolone oral tablet 10 mg, 2.5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	N/A
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Patients w/Turner's Syndrome or Ullrich-Turner Syndrome (oxandrolone only), management of protein catabolism w/burns or burn injury (oxandrolone only), AIDS wasting and cachexia

ANTIBIOTICS (INJECTABLE)

Products Affected

- *amikacin injection solution 1,000 mg/4 ml, 500 mg/2 ml*
- *ampicillin sodium*
- *ampicillin-sulbactam*
- *azithromycin intravenous*
- *aztreonam*
- **BICILLIN L-A**
- *cefazolin in dextrose (iso-os) intravenous piggyback 1 gram/50 ml*
- *cefazolin injection recon soln 100 gram, 300 g*
- *cefazolin intravenous*
- **CEFEPIME IN DEXTROSE 5 %**
- *cefepime in dextrose, iso-osm*
- *cefotaxime injection recon soln 1 gram*
- **CEFOTETAN IN DEXTROSE, ISO-OSM**
- *cefotetan injection*
- *cefoxitin*
- *cefoxitin in dextrose, iso-osm*
- *ceftazidime*
- **CEFTAZIDIME IN D5W**
- *ceftriaxone in dextrose, iso-os*
- **CEFTRIAZONE INJECTION RECON SOLN 100 GRAM**
- *ceftriaxone intravenous*
- *cefuroxime sodium injection recon soln 750 mg*
- *cefuroxime sodium intravenous*
- *ciprofloxacin in 5 % dextrose*
- **CLINDAMYCIN IN 0.9 % SOD CHLOR**
- *clindamycin in 5 % dextrose*
- *clindamycin phosphate injection*
- *clindamycin phosphate intravenous solution 600 mg/4 ml*
- **COLISTIN (COLISTIMETHATE NA)**
- *doxy-100*
- **ERYTHROCIN INTRAVENOUS RECON SOLN 500 MG**
- *gentamicin in nacl (iso-osm) intravenous piggyback 100 mg/100 ml, 60 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml*
- **GENTAMICIN IN NAACL (ISO-OSM) INTRAVENOUS PIGGYBACK 100 MG/50 ML, 120 MG/100 ML**
- *gentamicin injection solution 40 mg/ml*
- *gentamicin sulfate (ped) (pf)*
- *levofloxacin in d5w*
- *levofloxacin intravenous*
- *lincomycin*
- *linezolid in dextrose 5%*
- *linezolid-0.9% sodium chloride*
- *metro i.v.*
- *metronidazole in nacl (iso-os)*
- **MOXIFLOXACIN-SOD.ACE,SUL-WATER**
- *moxifloxacin-sod.chloride(iso)*
- *nafcillin*
- *nafcillin in dextrose iso-osm*
- **NUZYRA INTRAVENOUS**
- **ORBACTIV**
- *oxacillin injection*
- *penicillin g potassium*
- *pfizerpen-g*
- **PIPERACILLIN-TAZOBACTAM INTRAVENOUS RECON SOLN 13.5 GRAM**
- *polymyxin b sulfate*
- **SIVEXTRO INTRAVENOUS**
- **STREPTOMYCIN**
- *sulfamethoxazole-trimethoprim intravenous*
- **SYNERCID**
- *tazicef*
- **TEFLARO**
- *tigecycline*
- *tobramycin sulfate*

PA Criteria	Criteria Details
-------------	------------------

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	3 months
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

ANTIFUNGALS (IV)

Products Affected

- *caspofungin*
- *fluconazole in nacl (iso-osm) intravenous piggyback 200 mg/100 ml, 400 mg/200 ml*
- *voriconazole intravenous*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	3 months
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

ANTIFUNGALS, POLYENE

Products Affected

- ABELCET
- AMBISOME
- *amphotericin b*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	6 months
Other Criteria	B vs D coverage determination
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

ANTINEOPLASTICS, MONOCLONAL ANTIBODIES

Products Affected

- ABRAXANE
- ALIMTA
- ALIQOPA
- BAVENCIO
- BESPONSA
- BORTEZOMIB
- CYRAMZA
- DARZALEX
- ELZONRIS
- EMLICITI
- ENHERTU
- EVOMELA
- GAZYVA
- IMFINZI
- KADCYLA
- KANJINTI
- KEYTRUDA INTRAVENOUS SOLUTION
- LIBTAYO
- LUMOXITI
- MVASI
- MYLOTARG
- OGIVRI
- ONIVYDE
- OPDIVO
- PADCEV
- PERJETA
- POLIVY
- POTELIGEO
- RUXIENCE
- SARCLISA
- TECENTRIQ INTRAVENOUS SOLUTION 1,200 MG/20 ML (60 MG/ML), 840 MG/14 ML (60 MG/ML)
- *thiotepa*
- TRAZIMERA
- TRUXIMA
- UNITUXIN
- VECTIBIX
- VELCADE
- YERVOY INTRAVENOUS SOLUTION 200 MG/40 ML (5 MG/ML), 50 MG/10 ML (5 MG/ML)
- YONDELIS
- ZIRABEV

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months

PA Criteria	Criteria Details
Other Criteria	B vs D coverage determination
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

APOKYN

Products Affected

- APOKYN

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with a serotonin 5-HT3 Antagonist
Required Medical Information	Diagnosis, other therapies
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	1 year
Other Criteria	Parkinson's disease (PD)-approve if the patient has advanced PD, is experiencing off episodes such as muscle stiffness, slow movements, or difficulty starting movements, is currently receiving carbidopa/levodopa and has previously tried two other treatments for off episodes.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

ARANESP

Products Affected

- ARANESP (IN POLYSORBATE) INJECTION SOLUTION 100 MCG/ML, 200 MCG/ML, 25 MCG/ML, 300 MCG/ML, 40 MCG/ML, 60 MCG/ML
- ARANESP (IN POLYSORBATE) INJECTION SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Anemia w/CRF not on dialysis. A hemoglobin (Hb) of less than 10.0 g/dL for adults and less than or equal to 11 g/dL for children required for start, Hb has to be less than or equal to 11.5 g/dL adults or less than or equal to 12 g/dL in children if previously receiving epoetin alfa (EA), Mircera or Aranesp. Anemia due to myelosuppressive chemotx, Hb is 10.0 g/dL or less to start or less than or equal to 12.0 g/dL if previously on EA or Aranesp AND currently receiving myelosuppressive chemo. MDS, approve tx if Hb is 10 g/dL or less or serum erythropoietin level is 500 mU/mL or less to start. If the pt has previously been receiving Aranesp or EA, approve only if Hb is 12.0 g/dL or less. All conds, deny if Hb exceeds 12.0 g/dL.
Age Restrictions	MDS anemia = 18 years of age and older.
Prescriber Restrictions	MDS anemia, prescribed by or in consultation with, a hematologist or oncologist.
Coverage Duration	Anemia w/myelosupp=6 mos, Anemia CKD(dialysis)-3 years, no dialysis, MDS-1 year, Other=6 mos.
Other Criteria	N/A
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Anemia due to myelodysplastic syndrome (MDS)

ARCALYST

Products Affected

- ARCALYST

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent biologic therapy
Required Medical Information	N/A
Age Restrictions	Initial tx CAPS-Greater than or equal to 12 years of age.
Prescriber Restrictions	Initial tx CAPS-prescribed by, or in consultation with, a rheumatologist, geneticist, allergist/immunologist, or dermatologist.
Coverage Duration	3 mos initial, 3 years cont
Other Criteria	CAPS renewal - approve if the patient has had a response as determined by the prescriber.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

ARIKAYCE

Products Affected

- ARIKAYCE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, previous medication history
Age Restrictions	MAC-18 years and older
Prescriber Restrictions	MAC-Prescribed by a pulmonologist, infectious disease physician or a physician who specializes in the treatment of MAC lung infections. Cystic fibrosis-prescribed by or in consultation with a pulmonologist or physician who specializes in the treatment of cystic fibrosis
Coverage Duration	1 year
Other Criteria	MAC Lung disease-approve if the patient has NOT achieved negative sputum cultures for Mycobacterium avium complex after a background multidrug regimen AND Arikayce will be used in conjunction to a background multidrug regimen. Note-a multidrug regimen typically includes a macrolide (azithromycin or clarithromycin), ethambutol and a rifamycin (rifampin or rifabutin). Cystic fibrosis-patient has pseudomonas aeruginosa in culture of the airway.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Cystic fibrosis pseudomonas aeruginosa infection

ATYPICAL ANTIPSYCHOTIC

Products Affected

- FANAPT ORAL TABLET
- FANAPT ORAL TABLETS,DOSE PACK
- *paliperidone oral tablet extended release*
24hr 1.5 mg, 3 mg, 6 mg, 9 mg
- VRAYLAR ORAL CAPSULE
- VRAYLAR ORAL CAPSULE,DOSE PACK

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Approve if the patient has tried two of the following: olanzapine, quetiapine fumarate, risperidone, ziprasidone. Approve requests for paliperidone ER in Schizoaffective Disorder without the trial of other treatment.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

AUBAGIO

Products Affected

- AUBAGIO

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use of Aubagio with other disease-modifying agents used for multiple sclerosis (MS)
Required Medical Information	Relapsing form of MS
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or MS specialist.
Coverage Duration	Authorization will be for 1 year.
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

AURYXIA

Products Affected

- AURYXIA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

AUSTEDO

Products Affected

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or a psychiatrist
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

AVONEX

Products Affected

- AVONEX INTRAMUSCULAR PEN INJECTOR KIT
- AVONEX INTRAMUSCULAR SYRINGE KIT

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use of other disease-modifying agent used for multiple sclerosis
Required Medical Information	Relapsing form of Multiple Sclerosis (MS) diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or after consultation with a neurologist or an MS specialist.
Coverage Duration	Authorization will be for 3 years.
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

BENLYSTA

Products Affected

- BENLYSTA INTRAVENOUS RECON SOLN 120 MG, 400 MG
- BENLYSTA SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with other biologics or with cyclophosphamide intravenous (IV)
Required Medical Information	Diagnosis, medications that will be used in combination, autoantibody status
Age Restrictions	18 years and older (initial).
Prescriber Restrictions	Prescribed by or in consultation with a rheumatologist, clinical immunologist, nephrologist, neurologist or dermatologist (initial and continuation)
Coverage Duration	Initial-4 months, cont-3 years
Other Criteria	Initial-The patient has autoantibody-positive SLE (i.e., positive for antinuclear antibodies [ANA] and/or anti-double-stranded DNA antibody [anti-dsDNA]) AND Benlysta is being used concurrently with at least one other standard therapy (i.e., antimalarials [e.g., hydroxychloroquine], a systemic corticosteroid [e.g., prednisone], and/or other immunosuppressants [e.g., azathioprine, mycophenolate mofetil, methotrexate]) unless the patient is determined to be intolerant due to a significant toxicity, as determined by the prescribing physician. Continuation-Benlysta is being used concurrently with at least one other standard therapy (i.e., antimalarials [e.g., hydroxychloroquine], a systemic corticosteroid [e.g., prednisone], and/or other immunosuppressants [e.g., azathioprine, mycophenolate mofetil, methotrexate]) unless the patient is determined to be intolerant due to a significant toxicity, as determined by the prescribing physician AND The patient has responded to Benlysta as determined by the prescriber.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

BETASERON

Products Affected

- BETASERON SUBCUTANEOUS KIT

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with other disease-modifying agent used for multiple sclerosis
Required Medical Information	Relapsing form of Multiple Sclerosis (MS) diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or after consultation with a neurologist or an MS specialist.
Coverage Duration	Authorization will be for 3 years.
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

BOTOX

Products Affected

- BOTOX

PA Criteria	Criteria Details
Exclusion Criteria	cosmetic uses (eg, facial rhytides, frown lines, glabellar wrinkling, horizontal neck rhytides, mid and lower face and neck rejuvenation, platysmal bands, rejuvenation of the peri-orbital region)
Required Medical Information	None
Age Restrictions	None
Prescriber Restrictions	Migraine headache prophylaxis in patients with chronic migraine if prescribed by, or after consultation with, a neurologist or HA specialist
Coverage Duration	Authorization will be for 12 months
Other Criteria	<ul style="list-style-type: none"> •Blepharospasm Associated with Dystonia or Strabismus-approve •Cervical Dystonia (spasmodic torticollis)-approve •Hyperhidrosis, primary axillary-approve •Chronic low back pain after trial with at least 2 other pharmacologic therapies (eg, NSAID, antispasmodics, muscle relaxants, opioids, antidepressants) and if being used as part of a multimodal therapeutic pain management program. •Essential tremor after a trial with at least 1 other pharmacologic therapy (eg, primidone, propranolol, benzodiazepines, gabapentin, topiramate). •Migraine Headache Prophylaxis in patients with Chronic migraine -must have 15 or more migraine headache days per month with headache lasting 4 hours per day or longer (prior to initiation of Botox therapy) AND have tried at least two other prophylactic pharmacologic therapies, each from a different pharmacologic class (e.g., beta-blocker, anticonvulsant, tricyclic antidepressant). •Urinary incontinence associated with a neurological condition (e.g., spinal cord injury, multiple sclerosis) approve after a trial with at least one other pharmacologic therapy (e.g., anticholinergic medication). •Overactive Bladder with symptoms of Urge Urinary Incontinence,

PA Criteria	Criteria Details
	Urgency and Frequence-approve if the patient has tried at least one other pharmacologic therapy <ul style="list-style-type: none"> •Spasticity, lower limb-approve •Spasticity, upper limb-approve
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Achalasia, Anal Fissure (anal sphincter), Chronic facial pain/pain associated with TMJ dysfunction, Chronic low back pain, Hyperhidrosis (Palmar/Plantar, facial), Myofascial pain, Sialorrhea (chronic), Spasticity (other than lower and upper limb (eg, due to cerebral palsy, stroke, brain injury, spinal cord injury, MS, hemifacial spasm)), Essential tremor, Dystonia other than cervical (eg, focal dystonias, tardive dystonia, anismus, laryngeal dystonia/spasmodic dysphonia), Frey's syndrome (gustatory sweating), Ophthalmic disorders (other than blepharospasm or Strabismus (eg, esotropia, exotropia, nystagmus, facial nerve paresis))

C1 ESTERASE INHIBITORS

Products Affected

- HAEGARDA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	prescribed by or in consultation with an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

CAPLYTA

Products Affected

- CAPLYTA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Approve if the patient has tried two of the following: olanzapine, quetiapine fumarate, risperidone, ziprasidone.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CARBAGLU

Products Affected

- CARBAGLU

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a metabolic disease specialist or a specialist who focuses in the treatment of metabolic diseases
Coverage Duration	Pt meets criteria with no genetic test - 3 mo approval. Pt had genetic test - 12 mo approval
Other Criteria	Approve if genetic testing confirmed a mutation leading to N-acetylglutamate synthase deficiency (NAGS) or if the patient has hyperammonemia.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

CAYSTON

Products Affected

- CAYSTON

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or a physician who specializes in the treatment of cystic fibrosis.
Coverage Duration	1 year
Other Criteria	Approve if the patient has <i>Pseudomonas aeruginosa</i> in culture of the airway (e.g., sputum culture, oropharyngeal culture, bronchoalveolar lavage culture).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

CEREZYME

Products Affected

- CEREZYME INTRAVENOUS RECON SOLN 400 UNIT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, genetic tests and lab results
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorder
Coverage Duration	1 year
Other Criteria	Gaucher Disease, Type 1-approve if there is demonstration of deficient beta-glucocerebrosidase activity in leukocytes or fibroblasts OR molecular genetic testing documenting glucocerebrosidase gene mutation
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

CHEMET

Products Affected

- CHEMET

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Blood lead level
Age Restrictions	Approve in patients between the age of 12 months and 18 years
Prescriber Restrictions	Prescribed by or in consultation with a professional experienced in the use of chelation therapy (eg, a medical toxicologist or a poison control center specialist)
Coverage Duration	Approve for 2 months
Other Criteria	Approve if Chemet is being used to treat acute lead poisoning (not as prophylaxis) and prior to starting Chemet therapy the patient's blood lead level was greater than 45 mcg/dL.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

CHORIONIC GONADOTROPINS

Products Affected

- CHORIONIC GONADOTROPIN,
HUMAN INTRAMUSCULAR
- NOVAREL
- PREGNYL

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CIALIS

Products Affected

- CIALIS ORAL TABLET 2.5 MG, 5 MG
- *tadalafil oral tablet 2.5 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Cialis (tadalafil) 2.5mg and 5mg are only covered under Part D for the treatment of benign prostatic hyperplasia (BPH). Cialis (tadalafil) can be approved with a non-D authorization for the indication of erectile dysfunction if the EGWP customer has the lifestyle buy-up
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CLOBAZAM

Products Affected

- *clobazam oral suspension*
- *clobazam oral tablet*
- SYMPAZAN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, other medications tried
Age Restrictions	2 years and older (initial therapy)
Prescriber Restrictions	Prescribed by or in consultation with a neurologist (initial therapy)
Coverage Duration	1 year
Other Criteria	Lennox-Gastaut Syndrome, initial therapy-patient has tried one of the following: lamotrigine, topiramate, rufinamide, felbamate, or Epidiolex. Treatment refractory seizures/epilepsy, initial therapy-patient has tried and/or is concomitantly receiving at least two other antiepileptic drugs (e.g., valproic acid, lamotrigine, topiramate, clonazepam, levetiracetam, zonisamide, felbamate). Continuation-prescriber confirms patient is responding to therapy.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Dravet Syndrome and treatment-refractory seizures/epilepsy

COPAXONE

Products Affected

- COPAXONE SUBCUTANEOUS
SYRINGE 20 MG/ML, 40 MG/ML

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with other disease-modifying agent used for multiple sclerosis
Required Medical Information	Relapsing form of Multiple Sclerosis (MS) diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or after consultation with a neurologist or an MS specialist.
Coverage Duration	Authorization will be for 1 year.
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

CORLANOR

Products Affected

- CORLANOR ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Previous use of a Beta-blocker, LVEF
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Chronic HF, adults- must have LVEF of less than or equal 35 percent (currently or prior to initiation of Corlanor therapy) AND tried or is currently receiving a Beta-blocker for HF (e.g., metoprolol succinate sustained-release, carvedilol, bisoprolol, carvedilol ER) unless the patient has a contraindication to the use of beta blocker therapy (e.g., bronchospastic disease such as COPD and asthma, severe hypotension or bradycardia). Heart failure due to dilated cardiomyopathy, children-approve.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

CRINONE

Products Affected

- CRINONE VAGINAL GEL 8 %

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Crinone can be approved with a non-D authorization for the indication of infertility if the EGWP customer has the fertility buy-up
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

CYSTARAN

Products Affected

- CYSTARAN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an ophthalmologist or a metabolic disease specialist or specialist who focuses in the treatment of metabolic diseases
Coverage Duration	1 year
Other Criteria	Approve if the patient has corneal cysteine crystal deposits confirmed by slit-lamp examination
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

DERMATOLOGICAL WOUND CARE AGENTS

Products Affected

- REGRANEX

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

DIFICID

Products Affected

- DIFICID

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years of age and older
Prescriber Restrictions	N/A
Coverage Duration	1 month
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

DUAVEE

Products Affected

- DUAVEE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	For the prevention of postmenopausal osteoporosis, trial, failure, or intolerance of raloxifene is required prior to the use of Duavee.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

DUPIXENT

Products Affected

- DUPIXENT SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with Xolair or another Anti-interleukin (IL) Monoclonal Antibody.
Required Medical Information	Diagnosis, prescriber specialty, other medications tried and length of trials
Age Restrictions	asthma/AD-12 years of age and older. Chronic Rhinosinusitis-18 years of age and older
Prescriber Restrictions	Atopic Dermatitis-Prescribed by or in consultation with an allergist, immunologist or dermatologist, asthma-prescribed by or in consultation with an allergist, immunologist or pulmonologist. Rhinosinusitis-prescribed by or in consultation with an allergist, immunologist or otolaryngologist.
Coverage Duration	AD-Initial-4 months, Cont-1 year, asthma/Rhinosinusitis-initial-6 months, continuation 1 year
Other Criteria	Atopic Dermatitis-Initial-meets both a and b: a.has used at least one medium, medium-high, high, and/or super-high-potency prescription topical corticosteroid OR has atopic dermatitis affecting ONLY the face, eyes/eyelids, skin folds, and/or genitalia and has tried tacrolimus ointment AND b.Inadequate efficacy was demonstrated with these previously tried topical prescription therapies, according to the prescribing physician.Continuation-Approve if the pt has responded to Dupixent therapy as determined by the prescribing physician. Asthma-Initial-approve if pt meets the following criteria (i, ii, and iii):i.Pt meets ONE of the following criteria (a or b):a)has a blood eosinophil level of greater than or equal to 150 cells per microliter within the previous 6 weeks or within 6 weeks prior to treatment with any anti-interleukin (IL) therapy or Xolair OR b)has oral corticosteroid-dependent asthma, per the prescriber AND ii.has received combination therapy with BOTH of the following (a and b): a)An inhaled corticosteroid (ICS) AND b)At least one additional asthma controller/maintenance medication (NOTE:An exception to the requirement for a trial of one additional asthma controller/maintenance medication can be made if the patient has already received anti-IL-5 therapy or Xolair used concomitantly with an ICS. Use of a combination

PA Criteria	Criteria Details
	<p>inhaler containing both an ICS and a LABA would fulfil the requirement for both criteria a and b) AND iii.asthma is uncontrolled or was uncontrolled prior to starting any anti-IL therapy or Xolair as defined by ONE of the following (a, b, c, d or e): a)experienced two or more asthma exacerbations requiring treatment with systemic corticosteroids in the previous year OR b)experienced one or more asthma exacerbation requiring hospitalization or an Emergency Department visit in the previous year OR c)has a forced expiratory volume in 1 second (FEV1) less than 80% predicted OR d)has an FEV1/forced vital capacity (FVC) less than 0.80 OR e)The patient's asthma worsens upon tapering of oral corticosteroid therapy. Continuation-Approve if meets the following criteria (i and ii): i.continues to receive therapy with one inhaled corticosteroid (ICS) or one ICS-containing combination inhaler AND ii.has responded to Dupixent therapy as determined by the prescribing physician. Chronic rhinosinusitis with Nasal Polyposis-Initial-pt is currently receiving therapy with an intranasal corticosteroid AND is experiencing significant rhinosinusitis symptoms such as nasal obstruction, rhinorrhea, or reduction/loss of smell according to the prescriber AND meets ONE of the following (a or b): a)has received treatment with a systemic corticosteroid within the previous 2 years or has a contraindication to systemic corticosteroid therapy OR b)has had prior surgery for nasal polyps. Continuation-approve if the pt continues to receive therapy with an intranasal corticosteroid AND pt has responded to Dupixent therapy as determined by the prescriber.</p>
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

ELAPRASE

Products Affected

- ELAPRASE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, genetic and lab test results
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders
Coverage Duration	1 year
Other Criteria	Approve if the patient has laboratory test demonstrating deficient iduronate-2-sulfatase activity in leukocytes, fibroblasts, or plasma OR a molecular genetic test demonstrating iduronate-2-sulfatase gene mutation
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

ENBREL

Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS RECON SOLN
- ENBREL SUBCUTANEOUS SYRINGE
- ENBREL SURECLICK

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with biologic therapy or targeted synthetic DMARD
Required Medical Information	Diagnosis, concurrent medications, previous therapies tried.
Age Restrictions	PP-4 years and older (initial therapy)
Prescriber Restrictions	Initial only-RA/AS/JIA/JRA,prescribed by or in consult w/ rheum. PsA, prescribed by or in consultation w/ rheumatologist or dermatologist.PP, prescribed by or in consult w/ dermatologist.GVHD,prescribed by or in consult w/ oncologist,hematologist,or physician affiliated w/ transplant center. Uveitis, prescribed by or in consultation with an ophthalmologist.
Coverage Duration	FDA dx-3 mo init, 3 yrs cont, uveitis init-3 mo, cont-12 mo.GVHD-1 mo init/3 mo cont.
Other Criteria	RA/PsA initial, patient has tried one conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic for RA are not required to step back and try a conventional synthetic DMARD). JIA/JRA initial, patient has tried another agent (e.g MTX, sulfasalazine, leflunomide, NSAID, or biologic DMARD (eg, etanercept, abatacept, infliximab, anakinra, tocilizumab) or will be starting on Enbrel concurrently with MTX, sulfasalazine, or leflunomide. Approve without trying another agent if pt has absolute contraindication to MTX, sulfasalazine, or leflunomide or if pt has aggressive disease. PP initial, approve if the patient meets one of the following criteria: 1) pt has tried at least one traditional systemic agent (eg, MTX, cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant (note: pts who have already tried a biologic for psoriasis are not required to step back and try a traditional agent first) OR 2) pt has a contraindication to MTX as determined by the prescribing physician. Uveitis initial, tried one of the following: periocular, intraocular, or systemic corticosteroid, immunosuppressives or other biologic therapy. GVHD, tried or currently is receiving with etanercept 1 conventional GVHD tx (high-dose systemic

PA Criteria	Criteria Details
	corticosteroid, CSA, tacrolimus, MM, thalidomide, antithymocyte globulin, etc.). Continuation-approve if the patient has had a response as determined by the prescriber. Clinical criteria incorporated into the Enbrel 25 mg quantity limit edit, approve additional quantity (to allow for 50 mg twice weekly dosing) if one of the following is met: 1) Patient has plaque psoriasis, OR 2) Patient has RA/JIA/PsA/AS and is started and stabilized on 50 mg twice weekly dosing, OR 3) Patient has RA and the dose is being increased to 50 mg twice weekly and patient has taken MTX in combination with Enbrel 50 mg once weekly for at least 2 months, unless MTX is contraindicated or intolerant, OR 4) Patient has JIA/PsA/AS and the dose is being increased to 50 mg twice weekly after taking 50 mg once weekly for at least 2 months.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Graft versus host disease (GVHD), Uveitis

EPCLUSA

Products Affected

- EPCLUSA

PA Criteria	Criteria Details
Exclusion Criteria	Combination use with other direct acting antivirals, excluding ribavirin.
Required Medical Information	Genotype, prescriber specialty, other medications tried or used in combination with requested medication
Age Restrictions	6 years or older
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician
Coverage Duration	Will be c/w AASLD guidance and inclusive of treatment already received for the requested drug
Other Criteria	Criteria will be applied consistent with current AASLD/IDSA guidance.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Indications consistent with current AASLD/IDSA guidance

EPIDIOLEX

Products Affected

- EPIDIOLEX

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, previous therapies
Age Restrictions	Patients 2 years and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

EPOETIN ALFA

Products Affected

- EPOGEN INJECTION SOLUTION 20,000 UNIT/2 ML, 20,000 UNIT/ML, 10,000 UNIT/ML, 2,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML
- PROCRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML,
- RETACRIT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	CRF anemia in patients not on dialysis.Hemoglobin (Hb) of less than 10.0 g/dL for adults or less than or equal to 11 g/dL for children to start.Hb less than or equal to 11.5 g/dL for adults or 12 g/dL or less for children if previously on epoetin alfa, Mircerca or Aranesp. Anemia w/myelosuppressive chemotx.pt must be currently receiving myelosuppressive chemo and Hb 10.0 g/dL or less to start.Hb less than or equal to 12.0 g/dL if previously on epoetin alfa or Aranesp.MDS, approve if Hb is 10 g/dL or less or serum erythropoietin level is 500 mU/mL or less to start.Previously receiving Aranesp or EA, approve if Hb is 12.0 g/dL or less. Anemia in HIV with zidovudine, Hb is 10.0 g/dL or less or endogenous erythropoietin levels are 500 mU/mL or less at tx start.Previously on EA approve if Hb is 12.0 g/dL or less. Surgical pts to reduce RBC transfusions - Hgb is less than or equal to 13, surgery is elective, nonvascular and non-cardiac and pt is unwilling or unable to donate autologous blood prior to surgery
Age Restrictions	MDS anemia = 18 years of age and older.
Prescriber Restrictions	MDS anemia, myelofibrosis-prescribed by or in consultation with, a hematologist or oncologist.
Coverage Duration	Chemo-6m,Transfus-1m, CKD(dialysis)-3yrs, Myelofibrosis-init-3 mo, cont-1 yr, all others-1 yr
Other Criteria	Myelofibrosis-Initial-patient has a Hb less than 10 or serum erythropoietin less than or equal to 500 Mu/mL. Cont-patient has a Hgb less than or equal to 12 and according to the prescriber the patient has had a response defined as Hb greater than or equal to 10 or an increase of greater than or equal to 2 g/dL.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.

PA Criteria	Criteria Details
Off-Label Uses	Anemia due to myelodysplastic syndrome (MDS), myelofibrosis

ERIVEDGE

Products Affected

- ERIVEDGE

PA Criteria	Criteria Details
Exclusion Criteria	BCC (La or Met) - must not have had disease progression while on Odomzo.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 3 years
Other Criteria	Locally advanced basal cell carcinoma (LABCC), approve if 1. the patient's BCC has recurred following surgery or radiation, OR 2. the patient is not a candidate for surgery and radiation therapy. Central nervous system cancer (this includes brain and spinal cord tumors)-approve if the patient has tried at least one chemotherapy agent and according to the prescriber, the patient has a mutation of the sonic hedgehog pathway.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Central nervous System Cancer

ERLEADA

Products Affected

- ERLEADA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	3 years
Other Criteria	Prostate cancer-non-metastatic, castration resistant and prostate cancer-metastatic, castration sensitive-approve if the requested medication will be used in combination with a gonadotropin-releasing hormone (GnRH) analog or if the patient has had a bilateral orchiectomy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

ESBRIET

Products Affected

- ESBRIET ORAL CAPSULE
- ESBRIET ORAL TABLET 267 MG, 801 MG

PA Criteria	Criteria Details
Exclusion Criteria	Combination use with nintedanib
Required Medical Information	N/A
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist
Coverage Duration	1 year
Other Criteria	IPF - must have FVC greater than or equal to 40 percent of the predicted value AND IPF must be diagnosed with either findings on high-resolution computed tomography (HRCT) indicating usual interstitial pneumonia (UIP) or surgical lung biopsy demonstrating UIP.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

EXTAVIA

Products Affected

- EXTAVIA

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with other disease-modifying agent used for multiple sclerosis
Required Medical Information	Relapsing form of Multiple Sclerosis (MS) diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or after consultation with a neurologist or an MS specialist.
Coverage Duration	Authorization will be for 3 years.
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

EYLEA

Products Affected

- EYLEA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Administered by or under the supervision of an ophthalmologist
Coverage Duration	3 years
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

FERRIPROX

Products Affected

- FERRIPROX

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Serum ferritin level
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist
Coverage Duration	1 year
Other Criteria	Initial therapy - approve if prior to starting therapy the serum ferritin level was greater than 2,500 mcg/L. Continuation therapy - approve if the patient is benefiting from therapy as confirmed by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

FIRAZYR

Products Affected

- *icatibant*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Patient must have a confirmed diagnosis of HAE.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

FIRDAPSE

Products Affected

- FIRDAPSE

PA Criteria	Criteria Details
Exclusion Criteria	History of seizures (initial therapy)
Required Medical Information	Diagnosis, seizure history, lab and test results
Age Restrictions	18 years and older (initial therapy)
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or a neuromuscular specialist (initial therapy)
Coverage Duration	Initial-3 months, Cont-1 year
Other Criteria	Initial therapy-Diagnosis confirmed by at least one electrodiagnostic study (e.g., repetitive nerve stimulation) OR anti-P/Q-type voltage-gated calcium channels (VGCC) antibody testing according to the prescribing physician. Continuation-patient continues to derive benefit (e.g., improved muscle strength, improvements in mobility) from Firdapse, according to the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

FORTEO

Products Affected

- FORTEO

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other medications for osteoporosis (eg, denosumab [Prolia], bisphosphonates, raloxifene, calcitonin nasal spray [Fortical], abaloparatide), except calcium and Vitamin D.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Auth will be for 2 years of total therapy between Tymlos/Bonsity/teriparatide over pt's lifetime
Other Criteria	Treatment of PMO, approve if pt has tried one oral bisphosphonate OR pt cannot take an oral bisphosphonate because the pt cannot swallow or has difficulty swallowing or the pt cannot remain in an upright position post oral bisphosphonate administration or pt has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried an IV bisphosphonate (ibandronate or zoledronic acid), OR pt has severe renal impairment (creatinine clearance less than 35 mL/min) or CKD or pt has had an osteoporotic fracture or fragility fracture. Increase bone mass in men (a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression) with primary or hypogondal osteoporosis/Treatment of GIO, approve if pt tried one oral bisphosphonate OR pt cannot take an oral bisphosphonate because the patient cannot swallow or has difficulty swallowing or the patient cannot remain in an upright position post oral bisphosphonate administration or has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried zoledronic acid (Reclast), OR pt has severe renal impairment (CrCL less than 35 mL/min) or has CKD or has had an osteoporotic fracture or fragility fracture.

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

GATTEX

Products Affected

- GATTEX 30-VIAL
- GATTEX ONE-VIAL

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	1 year and older
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist (initial and continuation)
Coverage Duration	1 year
Other Criteria	Initial-approve if the patient is currently receiving parenteral nutrition on 3 or more days per week or according to the prescriber, the patient is unable to receive adequate total parenteral nutrition required for caloric needs. Continuation-approve if the patient has experienced at least a 20 percent decrease from baseline in the weekly volume of parenteral nutrition.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

GILENYA

Products Affected

- GILENYA ORAL CAPSULE 0.5 MG

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use of Gilenya with other disease-modifying agents used for multiple sclerosis (MS).
Required Medical Information	For use in MS, patient has a relapsing form of MS.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, a neurologist or an MS specialist.
Coverage Duration	Authorization will be for 1 year.
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

GONADOTROPIN-RELEASING HORMONE AGONISTS - INJECTABLE LONG ACTING

Products Affected

- ELIGARD
- ELIGARD (3 MONTH)
- ELIGARD (4 MONTH)
- ELIGARD (6 MONTH)
- *leuprolide subcutaneous kit*
- LUPRON DEPOT
- LUPRON DEPOT (3 MONTH)
- LUPRON DEPOT (4 MONTH)
- LUPRON DEPOT (6 MONTH)
- LUPRON DEPOT-PED (3 MONTH)
INTRAMUSCULAR SYRINGE KIT
11.25 MG, 30 MG
- LUPRON DEPOT-PED
INTRAMUSCULAR KIT 11.25 MG, 15
MG, 7.5 MG (PED)
- TRIPTODUR

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	For the treatment of cancer diagnosis must be prescribed by or in consultation with an oncologist.
Coverage Duration	For abnormal uterine bleeding, uterine leiomyomata 6 mo. All other=12 mo
Other Criteria	N/A
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Ovarian cancer, breast cancer, prophylaxis or treatment of uterine bleeding in patients with hematologic malignancy or undergoing cancer treatment or prior to bone marrow/stem cell transplantation, head and neck cancer-salivary gland tumors

GROWTH HORMONES - GENOTROPIN

Products Affected

- GENOTROPIN
- GENOTROPIN MINIQUICK

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	GHD in Children/Adolescents. Pt meets one of the following-1-had 2 GH stim tests with the following-levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon and both are inadequate as defined by a peak GH response which is below the normal reference range of the testing laboratory OR had at least 1 GH test and results show inadequate response and has at least one risk factor for GHD (e.g., ht for age curve deviated down across 2 major height percentiles [e.g., from above the 25 percentile to below the 10 percentile], growth rate is less than the expected normal growth rate based on age and gender, low IGF-1 and/or IGFBP-3 levels). 2.brain radiation or tumor resection and pt has 1 GH stim test and results is inadequate response or has def in at least 1 other pituitary hormone (that is, ACTH, TSH, gonadotropin deficiency [LH and/or FSH] are counted as 1 def], or prolactin).3. congenital hypopituitarism and has one GH stim test with inadequate response OR def in at least one other pituitary hormone and/or the patient has the imaging triad of ectopic posterior pituitary and pituitary hypoplasia with abnormal pituitary stalk 4.pt has panhypopituitarism and has pituitary stalk agenesis, empty sella, sellar or supra-sellar mass lesion, or ectopic posterior pituitary bright spot on MRI or CT or pt has 3 or more pituitary hormone deficiencies or pt has had one GH test and results were inadequate 5.pt had a hypophysectomy. Cont-pt responding to therapy
Age Restrictions	ISS 5 y/o or older, SGA 2 y/o or older, SBS 18 y/o or older
Prescriber Restrictions	GHD (Initial tx children or adolescents w/o hypophysectomy), GHD adults or transitional adolescents, Noonan (initial), Prader Willi (initial for child/adult and cont tx in adults), SHOX (initial), SGA (initial) - prescribed by or in consultation with an endocrinologist. CKD (initial) endocrinologist or nephrologist.
Coverage Duration	ISS - 6 mos intial, 12 months cont tx, SBS-1 month, others 12 mos
Other Criteria	GHD initial in adults and adolescents 1. endocrine must certify not being prescribed for anti-aging or to enhance athletic performance, 2. has either

PA Criteria	Criteria Details
	<p>childhood onset or adult onset resulting from GHD alone, multiple hormone deficiency from pituitary dx, hypothalamic dz, pituitary surgery, cranial radiation tx, tumor treatment, TBI or subarachnoid hemorrhage, AND 3. meets one of the following - A. has known mutations, embryonic lesions, congenital or genetic defects or structural hypothalamic pituitary defects, B. 3 or more pituitary hormone def (ACTH, TSH, LH/FSH, or prolactin, IGF1 less than 84 mcg/L (Esoterix RIA), AND other causes of low serum IGF-1 have been excluded, C. Neg response to ONE preferred GH stim test (insulin peak response less than or equal to 5 mcg/L, Glucagon peak less than or equal to 3 mcg/L (BMI is less than or equal to 25), less than or equal to 3 and BMI is greater than or equal to 25 and less than or equal to 30 with a high pretest probability of GH deficiency, less than or equal to 1 and BMI is greater than or equal to 25 and less than or equal to 30 with a low pretest probability of GH deficiency or less than or equal to 1 mcg/L (BMI is greater than 30), if insulin and glucagon contraindicated then Arginine alone test with peak of less than or equal to 0.4 mcg/L, or Macrilen peak less than 2.8 ng/ml AND BMI is less than or equal to 40 AND if a transitional adolescent must be off tx for at least one month before retesting. ISS initial - baseline ht less than the 1.2 percentile or a standard deviation score (SDS) less than -2.25 for age and gender, open epiphyses, does not have CDGP and height velocity is either growth rate (GR) is a. less than 4 cm/yr for pts greater than or equal to 5 or b. growth velocity is less than 10th percentile for age/gender. CKD initial - CKD defined by abnormal CrCl. Noonan initial - baseline height less than 5th percentile. SHOX initial - SHOX def by chromo analysis, open epiphyses, height less than 3rd percentile for age/gender. SGA initial - baseline ht less than 5th percentile for age/gender and born SGA (birth weight/length that is more than 2 SD below mean for gestational age/gender and didn't have sufficient catch up growth by 2-4 y/o). SBS initial pt receiving specialized nutritional support. Continuation of tx- approve if the patient has experienced improvement, according to the prescribing physician.</p>
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	SHOX, SBS, CKD

HALAVEN

Products Affected

- HALAVEN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	For metastatic breast cancer, documentation of prior treatment with an anthracycline and a taxane. For unresectable or metastatic liposarcoma, documentation of prior treatment with an anthracycline-containing regimen.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	For metastatic breast cancer, patients must have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. B vs D coverage determination.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

HARVONI

Products Affected

- HARVONI ORAL PELLETS IN PACKET 33.75-150 MG, 45-200 MG
- HARVONI ORAL TABLET 45-200 MG, 90-400 MG

PA Criteria	Criteria Details
Exclusion Criteria	Combination use with other direct acting antivirals, excluding ribavirin
Required Medical Information	N/A
Age Restrictions	3 years or older
Prescriber Restrictions	Prescribed by or in consultation w/ GI, hepatologist, ID, or a liver transplant MD
Coverage Duration	Will be c/w AASLD guidance and inclusive of treatment already received for the requested drug
Other Criteria	Criteria will be applied consistent with current AASLD/IDSA guidance.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Indications consistent with current AASLD/IDSA guidance

HETLIOZ

Products Affected

- HETLIOZ

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	patient is totally blind with no perception of light
Age Restrictions	18 years or older
Prescriber Restrictions	prescribed by, or in consultation with, a neurologist or a physician who specializes in the treatment of sleep disorders
Coverage Duration	6 mos initial, 12 mos cont
Other Criteria	Initial - dx of Non-24 is confirmed by either assessment of one physiologic circadian phase marker (e.g., measurement of urinary melatonin levels, dim light melatonin onset, assessment of core body temperature), or if assessment of physiologic circadian phase marker cannot be done, the diagnosis must be confirmed by actigraphy plus evaluation of sleep logs. Cont - Approve if pt has achieved adequate results with HetlioZ therapy according to the prescribing physician (e.g., entrainment, clinically meaningful or significant increases in nighttime sleep, clinically meaningful or significant decreases in daytime sleep).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

HIGH RISK MEDICATIONS - BENZTROPINE

Products Affected

- *benztropine oral*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	For all medically-accepted indications, approve if the prescriber confirms he/she has assessed risk versus benefit in prescribing benztropine for the patient and he/she would still like to initiate/continue therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

HIGH RISK MEDICATIONS - CARISOPRODOL

Products Affected

- *carisoprodol*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects. For patients concurrently taking multiple anticholinergic medications, the physician has assessed the risk.
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older.
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

HIGH RISK MEDICATIONS - CYCLOBENZAPRINE

Products Affected

- *cyclobenzaprine oral tablet 10 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve.
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	The physician has assessed risk versus benefit in using this High Risk Medication (HRM) in this patient and has confirmed that he/she would still like to initiate/continue therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

HIGH RISK MEDICATIONS - FIRST GENERATION ANTIHISTAMINES

Products Affected

- *promethazine oral*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	For promethazine, authorize use without a previous drug trial for all FDA-approved indications other than emesis, including cancer/chemo-related emesis. For hydroxyzine hydrochloride, authorize use without a previous drug trial for all FDA-approved indications other than anxiety. For the treatment of non-cancer/chemo related emesis, approve promethazine hydrochloride if the patient has tried a prescription oral anti-emetic agent (ondansetron, granisetron, dolasetron, aprepitant) for the current condition. Approve hydroxyzine hydrochloride if the patient has tried at least two other FDA-approved products for the management of anxiety. Prior to approval of promethazine and hydroxyzine, approve if the physician must have assessed risk versus benefit in prescribing the requested HRM for the patient and must confirm that he/she would still like to initiate/continue therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

HIGH RISK MEDICATIONS - PHENOBARBITAL

Products Affected

- *phenobarbital oral elixir*
- *phenobarbital oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	Coverage is not provided for use in sedation/insomnia.
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	For the treatment of seizures, approve only if the patient is currently taking phenobarbital.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

HRM - ANTIDEMENTIA AGENTS

Products Affected

- *ergoloid*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects, AND the physician has documented that the patient has tried and failed two (2) safer formulary alternatives or provided clinical rationale why two safer formulary alternatives are not appropriate for the patient.
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older.
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Safer alternatives are: donepezil, galantamine and rivastigmine.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

HRM - BUTALBITAL COMBINATIONS

Products Affected

- *ascomp with codeine*
- *bupap oral tablet 50-300 mg*
- *butalbital compound w/codeine*
- *butalbital-acetaminop-caf-cod*
- *butalbital-acetaminophen oral tablet 50-300 mg, 50-325 mg*
- *butalbital-acetaminophen-caff oral capsule*
- *butalbital-acetaminophen-caff oral tablet 50-325-40 mg*
- *butalbital-aspirin-caffeine oral capsule*
- *codeine-butalbital-asa-caff*
- *tencon oral tablet 50-325 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects, AND the physician has documented that the patient has tried and failed two (2) safer formulary alternatives or provided clinical rationale why two safer formulary alternatives are not appropriate for the patient.
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older.
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Safer alternatives are: naproxen sodium and ibuprofen.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

HRM - GLYBURIDE

Products Affected

- *glyburide*
- *glyburide micronized*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects, AND the physician has documented that the patient has tried and failed glipizide or provided clinical rationale as to why that safer formulary alternative is not appropriate for the patient.
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older.
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

HRM - GLYBURIDE/METFORMIN

Products Affected

- *glyburide-metformin*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects, AND the physician has documented that the patient has tried and failed glipizide-metformin or provided clinical rationale why that safer formulary alternative is not appropriate for the patient.
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older.
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

HRM - SKELETAL MUSCLE RELAXANTS

Products Affected

- *carisoprodol-aspirin*
- *carisoprodol-aspirin-codeine*
- *chlorzoxazone oral tablet 500 mg*
- *cyclobenzaprine oral tablet 7.5 mg*
- *metaxalone*
- *methocarbamol oral*
- *orphenadrine citrate oral*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects. For patients concurrently taking multiple anticholinergic medications, the physician has assessed the risk.
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older.
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

HRM - TRIHEXYPHENIDYL

Products Affected

- *trihexyphenidyl*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	The physician has documented the indication for the continued use of the HRM (high risk med) with an explanation of the specific benefit established with the medication and how that benefit outweighs the potential risk, AND the physician will continue to monitor for side effects. For patients concurrently taking multiple anticholinergic medications, the physician has assessed the risk.
Age Restrictions	Automatic approval if member is less than 65 years of age. Prior authorization required for age 65 or older.
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

HUMIRA

Products Affected

- HUMIRA PEN KIT 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML
- HUMIRA PEN CROHNS-UC-HS START
- HUMIRA PEN PSOR-UVEITS-ADOL HS
- HUMIRA SUBCUTANEOUS SYRINGE KIT 10 MG/0.2 ML, 20 MG/0.4 ML, 40 MG/0.8 ML
- HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE
- HUMIRA(CF) PEN CROHNS-UC-HS
- HUMIRA(CF) PEN PSOR-UV-ADOL HS
- HUMIRA(CF) PEN SUBCUTANEOUS INJECTOR KIT 40 MG/0.4 ML
- HUMIRA(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with biologic therapy or targeted synthetic DMARD
Required Medical Information	Diagnosis, concurrent medications, previous therapies tried
Age Restrictions	Crohn's disease (CD), 6 or older (initial therapy only). Ulcerative colitis (UC), 18 or older (initial therapy only)
Prescriber Restrictions	Initial therapy only all dx-RA/JIA/JRA/Ankylosing spondylitis, prescribed by or in consultation with rheumatologist. Psoriatic arthritis (PsA), prescribed by or in consultation with a rheumatologist or dermatologist. Plaque psoriasis (PP), prescribed by or in consultation with a dermatologist. UC/ CD, prescribed by or in consultation with a gastroenterologist. HS - dermatologist.UV-ophthalmologist
Coverage Duration	initial 3 mo, cont tx 3 years.
Other Criteria	RA/PsA initial, patient has tried one conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic for RA are not required to step back and try a conventional synthetic DMARD). JIA/JRA initial, patient has tried another agent (e.g MTX, sulfasalazine, leflunomide, NSAID, or biologic DMARD (eg, etanercept, abatacept, infliximab, anakinra, tocilizumab) or will be starting on Humira concurrently with MTX, sulfasalazine, or leflunomide. Approve without trying another agent if pt has absolute contraindication to MTX, sulfasalazine, or leflunomide or if pt has aggressive disease. PP initial,

PA Criteria	Criteria Details
	<p>approve if the patient meets one of the following criteria: 1) pt has tried at least one traditional systemic agent (eg, MTX, cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant (note: pts who have already tried a biologic for psoriasis are not required to step back and try a traditional agent first) OR 2) pt has a contraindication to MTX as determined by the prescribing physician. CD initial, approve if the patient meets ONE of the following criteria: 1) patient has tried or is currently taking corticosteroids, or corticosteroids are contraindicated, OR 2) patient has tried one other agent for CD. UC initial, approve if the patient has had a trial of one systemic agent for UC. Uveitis initial, tried one of the following: periocular, intraocular, or systemic corticosteroid, immunosuppressives or other biologic therapy. HS initial, tried ONE other therapy (e.g., intralesional or oral corticosteroids, systemic antibiotics, isotretinoin). Continuation-approve if the patient has had a response as determined by the prescriber. Clinical criteria incorporated into the Humira 40 mg quantity limit edit allow for approval of additional quantities to accommodate induction dosing. The allowable quantity is dependent upon the induction dosing regimen for the applicable FDA-labeled indications as outlined in product labeling.</p>
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

IMMUNE SUPPRESSANTS - TRANSPLANT RELATED

Products Affected

- ASTAGRAF XL
- ATGAM
- AZASAN
- *azathioprine*
- *azathioprine sodium*
- CELLCEPT
- *cyclosporine intravenous*
- *cyclosporine modified*
- *cyclosporine oral capsule*
- ENVARUS XR
- *everolimus (immunosuppressive) oral tablet 0.25 mg, 0.5 mg, 0.75 mg*
- *engraf oral capsule 100 mg, 25 mg*
- *engraf oral solution*
- *mycophenolate mofetil*
- *mycophenolate mofetil (hcl)*
- *mycophenolate sodium*
- MYFORTIC
- NEORAL
- PROGRAF
- RAPAMUNE
- SANDIMMUNE ORAL SOLUTION
- *sirolimus*
- *tacrolimus oral*
- ZORTRESS ORAL TABLET 1 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	B vs D coverage determination
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

INCRELEX

Products Affected

- INCRELEX

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Patients 2 years of age or older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

INFLIXIMAB

Products Affected

- RENFLEXIS

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with Biologic DMARD or Targeted Synthetic.
Required Medical Information	Diagnosis, concurrent medication, previous medications tried
Age Restrictions	CD and UC- Pts aged 6 years or more (initial therapy). PP-18 years and older (initial therapy)
Prescriber Restrictions	Prescribed by or in consultation with: RA/Ankylosing spondylitis/Still's disease/JIA/JRA-rheumatologist (initial therapy); Plaque Psoriasis/Pyoderma gangrenosum/Hidradenitis suppurativa-dermatologist (initial therapy), Psoriatic Arthritis-rheumatologist or dermatologist (initial therapy), Crohn's Disease/UC-gastroenterologist (initial therapy), Uveitis ophthalmologist (initial therapy), GVHD-a physician affiliated with a transplant center, oncologist, or hematologist (initial therapy), Behcet's Disease- rheumatologist, dermatologist, ophthalmologist, gastroenterologist, or neurologist (initial therapy), Sarcoidosis-pulmonol, ophthalmol, or dermatol (initial therapy).
Coverage Duration	FDA ind initial - 3 mos, cont 1 year, GVHD initial-1 month, cont-3 months, Pyoderma Gangrenosum-initial 4 months, cont 1 year, all others-initial 3 months, cont-12 mo
Other Criteria	<ul style="list-style-type: none"> •RA initial, patient has tried ONE conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic for RA are not required to step back and try a conventional synthetic DMARD). •CD approve if the pt has tried corticosteroid (CS) or if CSs contraindicated or if currently on CS or if the patient has tried one other conventional systemic therapy for CD OR the patient has enterocutaneous (perianal or abdominal) or rectovaginal fistulas OR the patient has had ileocolonic resection. Note-a previous trial of a biologic also counts as a trial of one other agent for Crohn's disease. •Ulcerative colitis (UC).Tried one systemic agent or was intolerant to one of these agents OR the patient has pouchitis AND has tried therapy with an

PA Criteria	Criteria Details
	<p>antibiotic, probiotic, corticosteroid enema, or mesalamine enema. Note-a previous trial of a biologic also counts as a trial of one systemic agent for UC.</p> <ul style="list-style-type: none"> •Behcet's. Pt has tried at least one conventional tx (eg, systemic CSs, immunosuppressants [e.g., AZA, MTX, MM, CSA, tacrolimus, chlorambucil, cyclophosphamide] or interferon alfa). NOTE: An exception to the requirement for a trial of one conventional therapy can be made if the patient has already had a trial of at least one tumor necrosis factor for Behcet's disease. These patients are not required to "step back" and try a conventional therapy) OR has ophthalmic manifestations. •SD.Tried CS AND 1 conventional synthetic DMARD (eg, MTX) for 2 mos, or was intolerant. •UV.Approve if the patient has tried one of the following therapies- periocular/intraocular CS, systemic CS or immunosuppressant (eg, MTX, MM, CSA, AZA, CPM)An exception can be made if the patient has already had a trial of an etanercept or adalimumab product. •Sarcoidosis.Tried CS and immunosuppressant (eg, MTX, AZA, CSA, chlorambucil), or chloroquine, or thalidomide). •Pyoderma gangrenosum (PG).Tried one systemic CS or immunosuppressant (eg, mycophenolate, CSA) for 2 mos or was intolerant to one of these agents. •Hidradenitis suppurativa (HS).Tried 1 one other therapy(eg, intralesional/oral CS, systemic antibiotic, isotretinoin). •GVHD.Tried 1 at least one conventional systemic treatment (eg, high-dose CS, antithymocyte globulin, CSA, thalidomide, tacrolimus, MM, etc.) •JIA/JRA (regardless of type of onset) Note-this includes patients with juvenile spondyloarthritis/active sacroiliac arthritis-approve if pt has tried 1 other medication for this condition (eg, MTX, sulfasalazine, or leflunomide, an NSAID, or one biologic DMARD or the pt has aggressive disease. •PP- approve if the patient has tried at least at least one traditional systemic agent for psoriasis for at least 3 months, unless intolerant or the patient has a contraindication to methotrexate (MTX), as determined by the prescriber. Note-A previous trial of a biologic also counts as a trial of a systemic agent. •cont tx - approve if patient has had a response, as determined by the prescriber.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.

PA Criteria	Criteria Details
Off-Label Uses	Patients already started on infliximab for a covered use, Behcet's disease, Still's disease, Uveitis, Pyoderma gangrenosum, Hidradenitis suppurativa,, Graft-versus-host disease, Juvenile Idiopathic Arthritis (JIA)/JRA, Sarcoidosis

INTRAROSA

Products Affected

- INTRAROSA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

KALYDECO

Products Affected

- KALYDECO ORAL GRANULES IN PACKET
- KALYDECO ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	Combination use with Orkambi, Trikafta or Symdeko
Required Medical Information	N/A
Age Restrictions	6 months of age and older
Prescriber Restrictions	prescribed by or in consultation with a pulmonologist or a physician who specializes in CF
Coverage Duration	1 year
Other Criteria	CF - must have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, D1270N, G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, G1349D, 2789+5G A, 3272-26A G, 3849+10kbC T, 711+3A G, E831X OR R117H AND must NOT be Homozygous for the F508del Mutation in the CFTR Gene or have unknown CFTR gene mutations.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

KINERET

Products Affected

- KINERET

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with another biologic DMARD or targeted synthetic DMARD
Required Medical Information	Diagnosis, concurrent medications, previous drugs tried.
Age Restrictions	N/A
Prescriber Restrictions	RA and Still's disease, prescribed by or in consultation with a rheumatologist. CAPS (Neonatal-Onset Multisystem Inflammatory Disease or Chronic Infantile Neurological Cutaneous and Articular [CINCA] syndrome), prescribed by or in consultation with a pediatrician, rheumatologist, geneticist, or dermatologist.
Coverage Duration	RA/CAPS initial 3 mos, cont 3 years. Stills 12 mos
Other Criteria	RA, approve if the patient has tried one of the following: Enbrel, Humira, Rinvoq. Still's Disease, approve if patient has tried a corticosteroid and has had an inadequate response to 1 conventional synthetic DMARD (eg, methotrexate) for at least 2 months or was intolerant to this therapy. Continuation-approve if the patient has had a response as determined by the prescriber.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Still's disease (SD). Juvenile Rheumatoid Arthritis.

KISQALI

Products Affected

- KISQALI FEMARA CO-PACK ORAL TABLET 200 MG/DAY(200 MG X 1)-2.5 MG, 400 MG/DAY(200 MG X 2)-2.5 MG, 600 MG/DAY(200 MG X 3)-2.5 MG
- KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	For use with an aromatase inhibitor in postmenopausal women or men as initial endocrine-based therapy, approve if the patient has tried Ibrance. For use with fulvestrant in patients with disease progression following endocrine therapy, approve if the patient has tried Ibrance.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

KORLYM

Products Affected

- KORLYM

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior surgeries
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist or a physician who specializes in the treatment of Cushing's syndrome
Coverage Duration	Endogenous Cushing's Syndrome-1 year. Pt awaiting surgery or response after radiotherapy-4 months
Other Criteria	Endogenous Cushing's Syndrome-Approve if, according to the prescribing physician, the patient is not a candidate for surgery or surgery has not been curative AND if Korlym is being used to control hyperglycemia secondary to hypercortisolism in patients who have type 2 diabetes mellitus or glucose intolerance.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Patients with Endogenous Cushing's Syndrome, awaiting surgery, Patients with Endogenous Cushing's syndrome, awaiting a response after radiotherapy

KUVAN

Products Affected

- KUVAN

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with Palynziq
Required Medical Information	Diagnosis, Phe concentration
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a specialist who focuses in the treatment of metabolic diseases (initial therapy)
Coverage Duration	Initial-12 weeks, Continuation-1 year
Other Criteria	Initial - approve. Continuation - approve if the patient has had a clinical response (e.g., cognitive and/or behavioral improvements) as determined by the prescribing physician OR patient had a 20% or greater reduction in blood Phe concentration from baseline.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

LETAIRIS

Products Affected

- *ambrisentan*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Pulmonary arterial hypertension (PAH) WHO Group 1-results of right heart cath
Age Restrictions	N/A
Prescriber Restrictions	For treatment of pulmonary arterial hypertension, ambrisentan must be prescribed by or in consultation with a cardiologist or a pulmonologist.
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Pulmonary arterial hypertension (PAH) WHO Group 1, are required to have had a right-heart catheterization to confirm diagnosis of PAH to ensure appropriate medical assessment.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

LUMIZYME

Products Affected

- LUMIZYME

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, genetic and lab test results
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a geneticist, neurologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders
Coverage Duration	1 year
Other Criteria	Approve if the patient has a laboratory test demonstrating deficient acid alpha-glucosidase activity in blood, fibroblasts, or muscle tissue OR patient has a molecular genetic test demonstrating acid alpha-glucosidase gene mutation
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

MAVYRET

Products Affected

- MAVYRET

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Genotype, prescriber specialty, other medications tried or used in combination with requested medication
Age Restrictions	12 years or older
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician
Coverage Duration	Criteria will be applied consistent with current AASLD/IDSA guidance.
Other Criteria	Criteria will be applied consistent with current AASLD/IDSA guidance.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Indications consistent with current AASLD/IDSA guidance

MEGACE

Products Affected

- *megestrol oral suspension 400 mg/10 ml (10 ml), 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml)*
- *megestrol oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	Coverage is not provided for weight gain for cosmetic reasons.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

METHAMPHETAMINE HCL

Products Affected

- *methamphetamine*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Patient must have failure, contraindication or intolerance to one formulary alternative such as dextroamphetamine, amphetamine/dextroamphetamine, methylphenidate or dexmethylphenidate before methamphetamine hcl is authorized.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

MOLECULAR TARGET INHIBITORS

Products Affected

- *abiraterone*
- AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 2 MG, 3 MG, 5 MG
- AFINITOR ORAL TABLET 10 MG, 2.5 MG, 5 MG, 7.5 MG
- ALECENSA
- ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG
- ALUNBRIG ORAL TABLETS,DOSE PACK
- AYVAKIT
- BALVERSA
- BOSULIF
- BRAFTOVI ORAL CAPSULE 75 MG
- BRUKINSA
- CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG
- CALQUENCE
- CAPRELSA ORAL TABLET 100 MG, 300 MG
- COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 140 MG/DAY(80 MG X1-20 MG X3), 60 MG/DAY (20 MG X 3/DAY)
- COPIKTRA
- COTELLIC
- DAURISMO ORAL TABLET 100 MG, 25 MG
- *erlotinib oral tablet 100 mg, 150 mg, 25 mg*
- *everolimus (antineoplastic)*
- FARYDAK ORAL CAPSULE 10 MG, 15 MG, 20 MG
- GILOTRIF
- IBRANCE
- ICLUSIG ORAL TABLET 15 MG, 45 MG
- IDHIFA
- *imatinib oral tablet 100 mg, 400 mg*
- IMBRUVICA ORAL CAPSULE 140 MG, 70 MG
- IMBRUVICA ORAL TABLET
- INLYTA ORAL TABLET 1 MG, 5 MG
- INREBIC
- IRESSA
- JAKAFI
- LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1), 12 MG/DAY (4 MG X 3), 14 MG/DAY(10 MG X 1-4 MG X 1), 18 MG/DAY (10 MG X 1-4 MG X2), 20 MG/DAY (10 MG X 2), 24 MG/DAY(10 MG X 2-4 MG X 1), 4 MG, 8 MG/DAY (4 MG X 2)
- LONSURF ORAL TABLET 15-6.14 MG, 20-8.19 MG
- LORBRENA ORAL TABLET 100 MG, 25 MG
- LYNPARZA ORAL TABLET
- MEKINIST ORAL TABLET 0.5 MG, 2 MG
- MEKTOVI
- NERLYNX
- NEXAVAR
- NINLARO
- PEMAZYRE
- PIQRAY
- POMALYST
- QINLOCK
- RETEVMO
- RUBRACA
- RYDAPT
- SPRYCEL ORAL TABLET 100 MG, 140 MG, 20 MG, 50 MG, 70 MG, 80 MG
- STIVARGA
- SUTENT
- SYNRIBO
- TABRECTA
- TAFINLAR
- TAGRISSO
- TALZENNA ORAL CAPSULE 0.25 MG, 1 MG
- TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG
- TAZVERIK

- TIBSOVO
- TUKYSA ORAL TABLET 150 MG, 50 MG
- TYKERB
- VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG
- VENCLEXTA STARTING PACK
- VIZIMPRO
- VOTRIENT
- XALKORI
- XOSPATA
- XPOVIO ORAL TABLET 100 MG/WEEK (20 MG X 5), 60 MG/WEEK (20 MG X 3), 80 MG/WEEK (20 MG X 4), 80MG TWICE WEEK (160 MG/WEEK)
- XTANDI
- ZEJULA
- ZELBORAF
- ZYDELIG
- ZYKADIA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

NAGLAZYME

Products Affected

- NAGLAZYME

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, genetic and lab test results
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders
Coverage Duration	1 year
Other Criteria	Approve if the patient has a laboratory test demonstrating deficient N-acetylgalactosamine 4-sulfatase (arylsulfatase B) activity in leukocytes or fibroblasts OR has a molecular genetic test demonstrating arylsulfatase B gene mutation.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

NATPARA

Products Affected

- NATPARA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist.
Coverage Duration	1 year
Other Criteria	Chronic hypoparathyroidism, initial therapy - approve if before starting Natpara, serum calcium concentration is greater than 7.5 mg/dL and 25-hydroxyvitamin D stores are sufficient per the prescribing physician. Chronic hypoparathyroidism, continuing therapy - approve if during Natpara therapy, the patient's 25-hydroxyvitamin D stores are sufficient per the prescribing physician, AND patient is responding to Natpara therapy, as determined by the prescriber.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

NAYZILAM

Products Affected

- NAYZILAM

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, other medications used at the same time
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	1 year
Other Criteria	Intermittent Episodes of Frequent Seizure Activity (i.e., seizure clusters, acute repetitive seizures)-approve if the patient is currently receiving maintenance antiepileptic medication(s).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

NMDA RECEPTOR ANTAGONIST

Products Affected

- *memantine oral capsule, sprinkle, er 24hr*
- *memantine oral solution*
- *memantine oral tablet 10 mg, 5 mg*
- *memantine oral tablets, dose pack*
- NAMZARIC

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Automatic approval if member is greater than 26 years of age. Prior Authorization is required for age 26 or younger.
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

NORTHERA

Products Affected

- NORTHERA ORAL CAPSULE 100 MG, 200 MG, 300 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Medication history
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or a neurologist
Coverage Duration	12 months
Other Criteria	NOH, approve if the patient meets ALL of the following criteria: a) Patient has been diagnosed with symptomatic NOH due to primary autonomic failure (Parkinson's disease, multiple system atrophy, pure autonomic failure), dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy, AND b) Patient has tried midodrine.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

NUBEQA

Products Affected

- NUBEQA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	3 years
Other Criteria	Prostate cancer - non-metastatic, castration resistant-approve if the requested medication will be used concurrently with a gonadotropin-releasing hormone (GnRH) agonist or if the patient has had a bilateral orchiectomy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

NUEDEXTA

Products Affected

- NUEDEXTA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

NULOJIX

Products Affected

- NULOJIX

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Documentation of Epstein-Barr virus serology and current medication regimen.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Documentation of use in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids. B vs D coverage determination.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

NUPLAZID

Products Affected

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

NUVIGIL/PROVIGIL

Products Affected

- *armodafinil*
- *modafinil oral tablet 100 mg, 200 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	Excessive sleepiness associated with Shift Work Sleep Disorder (SWSD) - approve if the patient is working at least 5 overnight shifts per month. Adjunctive/augmentation treatment for depression in adults (modafinil only) if the patient is concurrently receiving other medication therapy for depression. Excessive daytime sleepiness associated with obstructive sleep apnea/hypoapnea syndrome-approve. Excessive daytime sleepiness associated with Narcolepsy-approve if narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Excessive daytime sleepiness (EDS) associated with myotonic dystrophy - modafinil only. Adjunctive/augmentation for treatment of depression in adults - modafinil only.

OCALIVA

Products Affected

- OCALIVA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Prescriber specialty, lab values, prior medications used for diagnosis and length of trials
Age Restrictions	18 years and older (initial therapy)
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant physician (initial therapy)
Coverage Duration	6 months initial, 1 year continuation
Other Criteria	Initial treatment of PBC-Patient must meet both 1 and 2-1. Patient has a diagnosis of PBC as defined by TWO of the following:a)Alkaline phosphatase (ALP) elevated above the upper limit of normal as defined by normal laboratory reference values b)Positive anti-mitochondrial antibodies (AMAs) or other PBC-specific auto-antibodies, including sp100 or gp210, if AMA is negative c)Histologic evidence of primary biliary cholangitis (PBC) from a liver biopsy 2. Patient meets ONE of the following: a) Patient has been receiving ursodiol therapy for greater than or equal to 1 year and has had an inadequate response. b) Patient is unable to tolerate ursodiol therapy. Cont tx - approve if the patient has responded to Ocaliva therapy as determined by the prescribing physician (e.g., improved biochemical markers of PBC (e.g., alkaline phosphatase [ALP], bilirubin, gamma-glutamyl transpeptidase [GGT], aspartate aminotransferase [AST], alanine aminotransferase [ALT] levels)).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

OCREVUS

Products Affected

- OCREVUS

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with other Disease-Modifying Agents used for MS
Required Medical Information	N/A
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by, or in consultation with, a physician who specializes in the treatment of MS and/or a neurologist
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

OCTREOTIDE

Products Affected

- *octreotide acetate*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

ODOMZO

Products Affected

- ODOMZO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	BCC - Must not have had disease progression while on Erivedge (vismodegib).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	3 years
Other Criteria	Locally advanced BCC approve if the BCC has recurred following surgery/radiation therapy or if the patient is not a candidate for surgery AND the patient is not a candidate for radiation therapy, according to the prescribing physician. Metastatic BCC - approve.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Metastatic BCC

OFEV

Products Affected

- OFEV

PA Criteria	Criteria Details
Exclusion Criteria	Combination use with pirfenidone
Required Medical Information	N/A
Age Restrictions	18 years of age and older
Prescriber Restrictions	IPF-Prescribed by or in consultation with a pulmonologist. Interstitial lung disease associated with systemic sclerosis-prescribed by or in consultation with a pulmonologist or rheumatologist.
Coverage Duration	1 year
Other Criteria	IPF - must have FVC greater than or equal to 40 percent of the predicted value AND IPF must be diagnosed with either findings on high-resolution computed tomography (HRCT) indicating usual interstitial pneumonia (UIP) or surgical lung biopsy demonstrating UIP. Interstitial lung disease associated with systemic sclerosis-approve if the FVC is greater than or equal to 40 percent of the predicted value and the diagnosis is confirmed by high-resolution computed tomography. Chronic fibrosing interstitial lung disease-approve if the forced vital capacity is greater than or equal to 45% of the predicted value AND according to the prescriber the patient has fibrosing lung disease impacting more than 10% of lung volume on high-resolution computed tomography AND according to the prescriber the patient has clinical signs of progression.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

OPSUMIT

Products Affected

- OPSUMIT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	PAH WHO group, right heart catheterization
Age Restrictions	N/A
Prescriber Restrictions	PAH - must be prescribed by or in consultation with a cardiologist or a pulmonologist.
Coverage Duration	Authorization will be for 3 years.
Other Criteria	Pulmonary arterial hypertension (PAH) WHO Group 1 patients are required to have had a right-heart catheterization to confirm the diagnosis of PAH to ensure appropriate medical assessment.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

ORENCIA

Products Affected

- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with a Biologic DMARD or Targeted Synthetic DMARD.
Required Medical Information	Diagnosis, concurrent medications, previous therapies tried.
Age Restrictions	N/A
Prescriber Restrictions	Initial therapy only-RA and JIA/JRA prescribed by or in consultation with a rheumatologist. PsA-prescribed by or in consultation with a rheumatologist or dermatologist.
Coverage Duration	3 months initial, 3 years cont.
Other Criteria	RA, approve if the patient has tried one of the following: Enbrel, Humira, Rinvoq, Xeljanz. PsA, approve if the patient has tried one of the following: Enbrel, Humira, Stelara, Xeljanz. JIA/JRA, approve if the patient has tried one of the following: Enbrel, Humira. Continuation-approve if the patient has had a response as determined by the prescriber.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

ORKAMBI

Products Affected

- ORKAMBI ORAL GRANULES IN PACKET
- ORKAMBI ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	Combination use with Kalydeco, Trikafta or Symdeko.
Required Medical Information	N/A
Age Restrictions	2 years of age and older
Prescriber Restrictions	prescribed by or in consultation with a pulmonologist or a physician who specializes in CF
Coverage Duration	3 years
Other Criteria	CF - homozygous for the Phe508del (F508del) mutation in the CFTR gene (meaning the patient has two copies of the Phe508del mutation)
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

OSPHERA

Products Affected

- OSPHERA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

PHENYLBUTYRATE

Products Affected

- *sodium phenylbutyrate*

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of Ravicti and Buphenyl
Required Medical Information	Diagnosis, genetic tests and lab results
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a metabolic disease specialist (or specialist who focuses in the treatment of metabolic diseases)
Coverage Duration	Pt meets criteria with no genetic test - 3 mo approval. Pt had genetic test - 12 mo approval
Other Criteria	Urea cycle disorders-approve if genetic testing confirmed a mutation resulting in a urea cycle disorder or if the patient has hyperammonemia.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PHEOCHROMOCYTOMA

Products Affected

- DEMSER

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior medication trials
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist or a physician who specializes in the management of pheochromocytoma (initial therapy for phenoxybenzamine, initial and continuation therapy for Demser)
Coverage Duration	Authorization will be for 1 year
Other Criteria	If the requested drug is Demser for initial therapy, approve if the patient has tried a selective alpha blocker (e.g., doxazosin, terazosin or prazosin) AND the patient has tried phenoxybenzamine (brand or generic). If the requested drug is Demser for continuation therapy, approve if the patient is currently receiving Demser or has received Demser in the past.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PHOSPHODIESTERASE-5 INHIBITORS FOR PAH

Products Affected

- *alyq*
- *sildenafil (pulmonary arterial hypertension) oral tablet*
- *tadalafil (pulmonary arterial hypertension) oral tablet 20 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, right heart cath results
Age Restrictions	N/A
Prescriber Restrictions	For PAH, if prescribed by, or in consultation with, a cardiologist or a pulmonologist.
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Pulmonary arterial hypertension (PAH) WHO Group 1, are required to have had a right-heart catheterization to confirm diagnosis of PAH to ensure appropriate medical assessment. Clinical criteria incorporated into the quantity limit edits for sildenafil 20 mg tablets and suspension require confirmation that the indication is PAH (ie, FDA labeled use) prior to reviewing for quantity exception.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PROLASTIN-C

Products Affected

- PROLASTIN-C

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, pretreatment AAT serum concentration
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Alpha1-Antitrypsin (AAT) Deficiency with Emphysema (or COPD) - approve in patients with baseline (pretreatment) AAT serum concentration of less than 80 mg/dL (11 micromol/L).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PROMACTA

Products Affected

- PROMACTA ORAL POWDER IN PACKET 12.5 MG, 25 MG
- PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Cause of thrombocytopenia. Thrombocytopenia due to HCV-related cirrhosis, platelet counts. Severe aplastic anemia, platelet counts and prior therapy. MDS-platelet counts.
Age Restrictions	N/A
Prescriber Restrictions	Thrombocytopenia due to chronic ITP or Aplastic Anemia, approve if prescribed by, or after consultation with, a hematologist (initial therapy). Thrombocytopenia in pt with chronic Hep C, approve if prescribed by, or after consultation with, a gastroenterologist, hematologist, hepatologist, or a physician who specializes in infectious disease (initial therapy). MDS-presc or after consult with heme/onc (initial therapy).
Coverage Duration	Chronic ITP/MDS initial-3 mo, cont 1yr, AA-initial-4 mo, cont-1 yr, Thrombo/Hep C-1 yr
Other Criteria	Thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia purpura, initial-approve if the patient has a platelet count less than 30, 000 microliters or less than 50, 000 microliters and the patient is at an increased risk for bleeding AND the patient has tried ONE other therapy or has undergone a splenectomy. Cont-approve if the patient demonstrates a beneficial clinical response and remains at risk for bleeding complications. Treatment of thrombocytopenia in patients with Chronic Hepatitis C initial-approve if the patient will be receiving interferon-based therapy for chronic hepatitis C AND to allow for initiation of antiviral therapy if the patient has low platelet counts at baseline (eg, less than 75,000 microliters). Aplastic anemia initial - approve if the patient has low platelet counts at baseline/pretreatment (e.g., less than 30,000 microliters) AND tried one immunosuppressant therapy (e.g., cyclosporine, mycophenolate mofetil, sirolimus) OR patient will be using Promacta in combination with standard immunosuppressive therapy. Cont-approve if the patient demonstrates a beneficial clinical response. MDS initial-approve if patient has low- to intermediate-risk MDS AND the patient has a platelet count less than 30, 000 microliters or less than 50, 000 microliters

PA Criteria	Criteria Details
	and is at an increased risk for bleeding. Cont-approve if the patient demonstrates a beneficial clinical response and remains at risk for bleeding complications.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Thrombocytopenia in Myelodysplastic Syndrome (MDS)

PYRIMETHAMINE

Products Affected

- *pyrimethamine*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Patient's immune status
Age Restrictions	N/A
Prescriber Restrictions	Toxoplasma gondii Encephalitis, Chronic Maintenance and Prophylaxis (Primary)-prescribed by or in consultation with an infectious diseases specialist. Toxoplasmosis Treatment-prescribed by or in consultation with an infectious diseases specialist, a maternal-fetal medicine specialist, or an ophthalmologist.
Coverage Duration	12 months
Other Criteria	Toxoplasma gondii Encephalitis, Chronic Maintenance, approve if the patient is immunosuppressed. Toxoplasma gondii Encephalitis Prophylaxis (Primary), approve if the patient is immunosuppressed.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Chronic maintenance and prophylaxis of Toxoplasma Gondii encephalitis

REBIF

Products Affected

- REBIF (WITH ALBUMIN) MCG/0.5 ML, 8.8MCG/0.2ML-22
- REBIF REBIDOSE SUBCUTANEOUS MCG/0.5ML (6)
- PEN INJECTOR 22 MCG/0.5 ML, 44
- REBIF TITRATION PACK

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with other disease-modifying agent used for multiple sclerosis
Required Medical Information	Relapsing form of Multiple Sclerosis (MS) diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or after consultation with a neurologist or an MS specialist.
Coverage Duration	Authorization will be for 1 year.
Other Criteria	For patients requesting Rebif, approve if the patient has tried two of the following: Avonex, Betaseron, Copaxone, Gilenya and Tecfidera.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

RELISTOR INJECTION

Products Affected

- RELISTOR SUBCUTANEOUS SOLUTION
- RELISTOR SUBCUTANEOUS SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Patients 18 years of age or older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

REPATHA

Products Affected

- REPATHA
- REPATHA SURECLICK
- REPATHA PUSHTRONEX

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use of Juxtapid or Praluent.
Required Medical Information	LDL-C and response to other agents, prior therapies tried, medication adverse event history, medical history
Age Restrictions	ASCVD/HeFH/Primary Hyperlipidemia - 18 yo and older, HoFH 13 yo and older.
Prescriber Restrictions	Prescribed by, or in consultation with, a cardiologist, endocrinologist, or a physician who focuses in the treatment of CV risk management and/or lipid disorders
Coverage Duration	Approve for 3 years for ASCVD/HeFH/HoFH. Approve for 1 year for primary hyperlipidemia.
Other Criteria	Hyperlipidemia with HeFH - approve if: 1) diagnosis of HeFH AND 2) tried ONE high intensity statin (i.e. atorvastatin greater than or equal to 40 mg daily or Crestor greater than or equal to 20 mg daily) and LDL remains 70 mg/dL or higher unless pt is statin intolerant defined by experiencing statin related rhabdomyolysis or skeletal-related muscle symptoms while receiving separate trials of atorvastatin and Crestor and during both trials the symptoms resolved upon discontinuation. Hyperlipidemia with ASCVD -approve if: 1) has one of the following conditions: prior MI, h/o ACS, diagnosis of angina, h/o CVA or TIA, PAD, undergone a coronary or other arterial revascularization procedure, AND 2) tried ONE high intensity statin (defined above) and LDL remains 70 mg/dL or higher unless pt is statin intolerant (defined above). HoFH - approve if: 1) has one of the following: a) genetic confirmation of two mutant alleles at the LDLR, APOB, PCSK9, or LDLRAP1 gene locus, OR b) untreated LDL greater than 500 mg/dL (prior to treatment), OR c) treated LDL greater than or equal to 300 mg/dL (after treatment but prior to agents such as Repatha, Kynamro or Juxtapid), OR d) has clinical manifestations of HoFH (e.g., cutaneous xanthomas, tendon xanthomas, arcus cornea, tuberous xanthomas or xanthelasma), AND 2) tried ONE high intensity statin (defined above) for 8 weeks or longer and LDL remains 70 mg/dL or

PA Criteria	Criteria Details
	higher unless statin intolerant (defined above). Primary hyperlipidemia (not associated with ASCVD, HeFH, or HoFH)-approve if the patient has tried one high-intensity statin therapy (defined above) and ezetimibe for 8 weeks or longer and LDL remains 100 mg/dL or higher unless statin intolerant (defined above).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

REVLIMID

Products Affected

- REVLIMID

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis and previous therapies or drug regimens tried.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 3 years.
Other Criteria	Follicular lymphoma-approve if the patient is using Revlimid in combination with rituximab or has tried at least on prior therapy. MCL-approve. MZL-approve. Multiple myeloma-approve. MDS-approve if the patient meets one of the following: 1) Pt has symptomatic anemia, OR 2) Pt has transfusion-dependent anemia, OR 3) Pt has anemia that is not controlled with an erythroid stimulating agent (eg, Procrit [epoetin alfa injection], Aranesp [darbepoetin alfa injection]). Diffuse, Large B Cell Lymphoma (Non-Hodgkin's Lymphoma)-approve if the pt has tried at least one prior therapy. Myelofibrosis-approve if according to the prescriber the patient has anemia and the pt has serum erythropoietin levels greater than or equal to 500 mU/mL. Peripheral T-Cell Lymphoma or T-Cell Leukemia/Lymphoma-approve if the pt has tried at least one other therapy or regimen. CNS cancers (primary)-approve if according to the prescriber the patient has relapsed or refractory disease. Hodgkin lymphoma, classical-approve if the patient has relapsed or refractory disease. Castleman's disease-approve if the patient has relapsed/refractory or progressive disease. AIDS Related Kaposi's Sarcoma-approve if the patient has tried at least one regimen or therapy and the patient has relapsed or refractory disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Systemic Amyloidosis Light Chain, Diffuse Large B Cell Lymphoma

PA Criteria	Criteria Details
	(Non-Hodgkin's Lymphoma), Myelofibrosis, Castleman's Disease, Hodgkin lymphoma (Classical), Peripheral T-Cell Lymphoma, T-Cell Leukemia/Lymphoma, Central nervous system cancer (primary), Acquired immune deficiency syndrome (AIDS)-related Kaposi's sarcoma.

RINVOQ

Products Affected

- RINVOQ

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with biologic therapy or targeted synthetic DMARD
Required Medical Information	Diagnosis, concurrent medications, previous drugs tried.
Age Restrictions	18 years and older
Prescriber Restrictions	RA, prescribed by or in consultation with a rheumatologist.
Coverage Duration	Authorization will be for 3 months initial, 3 years cont.
Other Criteria	RA initial, patient has tried one conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic for RA are not required to step back and try a conventional synthetic DMARD).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

ROZLYTREK

Products Affected

- ROZLYTREK ORAL CAPSULE 100 MG, 200 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Solid Tumors-12 years and older
Prescriber Restrictions	N/A
Coverage Duration	3 years
Other Criteria	Solid Tumors-Approve if the patient meets the following criteria (A, B, and C): A) The patient has locally advanced or metastatic solid tumor AND B) The patient's tumor has neurotrophic receptor tyrosine kinase (NTRK) gene fusion AND C) The patient meets one of the following criteria (i or ii): i. The patient has progressed on prior therapies OR ii. There are no acceptable standard therapies and the medication is used as initial therapy. Non-Small Cell Lung Cancer-Approve if the patient has ROS1-positive metastatic disease.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

SAMSCA

Products Affected

- SAMSCA ORAL TABLET 15 MG, 30 MG

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with Jynarque.
Required Medical Information	Serum sodium less than 125 mEq/L at baseline or less marked hyponatremia, defined as serum sodium less than 135 mEq/L at baseline, that is symptomatic (eg, nausea, vomiting, headache, lethargy, confusion).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 30 days
Other Criteria	Hyponatremia - Pt must meet ONE of the following: 1. serum sodium less than 125 mEq/L at baseline, OR 2. marked hyponatremia, defined as less than 135 mEq/L at baseline, that is symptomatic (eg, nausea, vomiting, headache, lethargy, confusion), OR 3. patient has already been started on Samsca and has received less than 30 days of therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

SANDOSTATIN

Products Affected

- SANDOSTATIN LAR DEPOT INTRAMUSCULAR SUSPENSION, EXTENDED REL RECON

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, previous treatments/therapies
Age Restrictions	N/A
Prescriber Restrictions	Acromegaly-prescribed by or in consultation with an endocrinologist. All neuroendocrine tumors-prescribed by or in consultation with an oncologist, endocrinologist, or gastroenterologist. Pheochromocytoma/paraganglioma-prescribed by or in consultation with an endo/onc/neuro. Meningioma-prescribed by or in consultation with an oncologist, radiologist or neurosurgeon. Thymoma/Thymic carcinoma-prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Acromegaly-approve if the patient has (or had) a pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal based on age and gender for the reporting laboratory AND the patient meets i., ii., or iii: i. has had an inadequate response to surgery and/or radiotherapy or ii. is not an appropriate candidate for surgery and/or radiotherapy or iii. the patient is experiencing negative effects due to tumor size (e.g., optic nerve compression). Neuroendocrine Tumor(s) [NETs] of the Gastrointestinal Tract, Lung, Thymus (Carcinoid Tumors), and Pancreas (including glucagonomas, gastrinomas, vasoactive intestinal peptides-secreting tumors [VIPomas], insulinomas)-approve.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Pheochromocytoma/paraganglioma, Meningioma, Thyoma and thymic carcinoma

SIGNIFOR

Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older (initial therapy)
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist or a physician or specializes in the treatment of Cushing's syndrome (initial therapy)
Coverage Duration	Cushing's-Initial-4 mo, Cont therapy - 1 yr. Pt awaiting surgery/response after radiotherapy-4 mo
Other Criteria	Cushing's disease, initial therapy - approve if, according to the prescribing physician, the patient is not a candidate for surgery, or surgery has not been curative. Cushing's disease, continuation therapy - approve if the patient has already been started on Signifor/Signifor LAR and, according to the prescribing physician, the patient has had a response and continuation of therapy is needed to maintain response.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

SIRTURO

Products Affected

- SIRTURO ORAL TABLET 100 MG

PA Criteria	Criteria Details
Exclusion Criteria	Patients weighing less than 30 kg
Required Medical Information	Diagnosis, concomitant therapy
Age Restrictions	Patients 12 years of age or older
Prescriber Restrictions	Prescribed by, or in consultation with an infectious diseases specialist
Coverage Duration	9 months
Other Criteria	Tuberculosis, Pulmonary Multidrug-resistant or extensively drug resistant-prescribed as part of a combination regimen with other anti-tuberculosis agents
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

SKYRIZI

Products Affected

- SKYRIZI SUBCUTANEOUS SYRINGE KIT

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with biologic therapy or targeted synthetic DMARD
Required Medical Information	Diagnosis, Previous medication use
Age Restrictions	18 years of age and older (initial therapy)
Prescriber Restrictions	PP-Prescribed by or in consultation with a dermatologist (initial therapy)
Coverage Duration	3 mos initial, 3 years cont
Other Criteria	PP initial, approve if the patient meets one of the following criteria: 1) pt has tried at least one traditional systemic agent (eg, MTX, cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant (note: pts who have already tried a biologic for psoriasis are not required to step back and try a traditional agent first) OR 2) pt has a contraindication to MTX as determined by the prescribing physician. Continuation-approve if the patient has had a response as determined by the prescriber.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

SOMATULINE

Products Affected

- SOMATULINE DEPOT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, previous treatments/therapies
Age Restrictions	N/A
Prescriber Restrictions	Acromegaly-prescribed by or in consultation with an endocrinologist. Carcinoid syndrome-prescribed by or in consultation with an oncologist, endocrinologist or gastroenterologist. All neuroendocrine tumors-prescribed by or in consultation with an oncologist, endocrinologist, or gastroenterologist. Pheochromocytoma/paraganglioma-prescribed by or in consultation with an endo/onc/neuro.
Coverage Duration	1 year
Other Criteria	Acromegaly-approve if the patient has a pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal based on age and gender for the reporting laboratory AND the patient meets i., ii., or iii: i. has had an inadequate response to surgery and/or radiotherapy or ii. is not an appropriate candidate for surgery and/or radiotherapy or iii. the patient is experiencing negative effects due to tumor size (e.g., optic nerve compression). Neuroendocrine Tumor(s) [NETs] of the Gastrointestinal Tract, Lung, Thymus (Carcinoid Tumors), and Pancreas (including glucagonomas, gastrinomas, vasoactive intestinal peptide-secreting tumors [VIPomas], insulinomas)-approve. Carcinoid Syndrome-approve.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Pheochromocytoma/paraganglioma

SOMAVERT

Products Affected

- SOMAVERT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, previous therapy, concomitant therapy
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist
Coverage Duration	1 year
Other Criteria	Acromegaly-approve if patient meets ONE of the following (i, ii, or iii): i. patient has had an inadequate response to surgery and/or radiotherapy OR ii. The patient is NOT an appropriate candidate for surgery and/or radiotherapy OR iii. The patient is experiencing negative effects due to tumor size (e.g., optic nerve compression) AND patient has (or had) a pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal (ULN) based on age and gender for the reporting laboratory.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

STELARA

Products Affected

- STELARA INTRAVENOUS
- STELARA SUBCUTANEOUS SOLUTION
- STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with biologic therapy or targeted synthetic DMARD
Required Medical Information	Diagnosis, concurrent medications, previous drugs tried.
Age Restrictions	18 years and older CD/UC (initial therapy). PP-12 years and older (initial therapy).
Prescriber Restrictions	PP-Prescr/consult w/derm.PsA-prescr/consult w/rheum or derm.CD/UC-prescr/consult w/gastro.
Coverage Duration	PP/PsA Init-3mo,CD/UC load-approve 1 dose IV,CD/UC post IV load-SC 3 mo,cont tx-SC 3 yr
Other Criteria	PsA initial, patient has tried one conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic for RA are not required to step back and try a conventional synthetic DMARD). PP initial, approve if the patient meets one of the following criteria: 1) pt has tried at least one traditional systemic agent (eg, MTX, cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant (note: pts who have already tried a biologic for psoriasis are not required to step back and try a traditional agent first) OR 2) pt has a contraindication to MTX as determined by the prescribing physician. CD initial, approve if the patient meets ONE of the following criteria: 1) patient has tried or is currently taking corticosteroids, or corticosteroids are contraindicated, OR 2) patient has tried one other agent for CD. UC initial, approve if the patient has had a trial of one systemic agent for UC.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

SYLATRON

Products Affected

- SYLATRON SUBCUTANEOUS KIT
200 MCG, 300 MCG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Melanoma-approve if the patient has microscopic or gross nodal involvement and has had a complete lymphadenectomy within the past 84 days. Systemic mastocytosis-approve if the patient has aggressive systemic mastocytosis OR systemic mastocytosis with an associated hematologic malignancy OR osteopenia/osteoporosis with refractory bone pain and/or decreasing bone mineral density on bisphosphonate therapy. Myeloproliferative neoplasms-approve if the patient has symptomatic low-risk myelofibrosis or polycythemia vera or essential thrombocythemia.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Systemic mastocytosis, myeloproliferative neoplasms

SYMDEKO

Products Affected

- SYMDEKO

PA Criteria	Criteria Details
Exclusion Criteria	Patients with unknown CFTR gene mutations, Combination therapy with Orkambi, Kalydeco or Trikafta
Required Medical Information	Diagnosis, specific CFTR gene mutations
Age Restrictions	Six years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or a physician who specializes in CF
Coverage Duration	3 years
Other Criteria	CF - must have at least one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, 711+3A G, S945L, S977F, F1052V, E831X, K1060T, A1067T, R1070W, F1074L, D1152H, D1270N, 2789+5G A, 3272-26A G, or 3849 + 10kbC T OR the patient has two copies of the F508del mutation
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

SYMLIN

Products Affected

- SYMLINPEN 120
- SYMLINPEN 60

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 3 years.
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

SYNAGIS

Products Affected

- SYNAGIS

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Documentation of diagnosis.
Age Restrictions	24 months or younger
Prescriber Restrictions	N/A
Coverage Duration	6 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

TALTZ

Products Affected

- TALTZ SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with a Biologic DMARD or Targeted Synthetic DMARD.
Required Medical Information	Diagnosis, Previous medication use
Age Restrictions	PP-6 years and older (initial therapy), all other dx-18 years of age and older (initial therapy)
Prescriber Restrictions	All dx initial therapy only-PP-Prescribed by or in consultation with a dermatologist. PsA prescribed by or in consultation with a rheumatologist or a dermatologist. AS-prescribed by or in consultation with a rheum.
Coverage Duration	Initial authorization will be for 3 months, 3 years continuation.
Other Criteria	PP, approve if the patient has tried two of the following: Enbrel, Humira, Skyrizi, or Stelara. PsA, approve if the patient has tried two of the following: Enbrel, Humira, Stelara. AS, approve if the patient has tried one of the following: Enbrel or Humira. Non-radiographic Axial Spondyloarthritis, approve if the patient has objective signs of inflammation. Continuation-approve if the patient has had a response as determined by the prescriber.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

TARGRETIN ORAL

Products Affected

- *bexarotene*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, previous therapies tried
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or dermatologist (initial and continuation)
Coverage Duration	3 years
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

TARGRETIN TOPICAL

Products Affected

- TARGRETIN TOPICAL

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, previous therapies tried
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or dermatologist (initial and continuation)
Coverage Duration	3 years
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

TECFIDERA

Products Affected

- TECFIDERA ORAL
CAPSULE, DELAYED

RELEASE(DR/EC) 120 MG, 120 MG
(14)- 240 MG (46), 240 MG

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with other disease-modifying agents used for multiple sclerosis (MS)
Required Medical Information	MS, patient must have a relapsing form of MS
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or MS specialist.
Coverage Duration	Authorization will be for 1 year.
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

TERIPARATIDE

Products Affected

- TERIPARATIDE

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other medications for osteoporosis (eg, denosumab [Prolia], bisphosphonates, raloxifene, calcitonin nasal spray [Fortical], abaloparatide), except calcium and Vitamin D.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Auth will be for 2 years of total therapy between Tymlos/teriparatide over pt's lifetime
Other Criteria	Treatment of PMO, approve if pt has tried one oral bisphosphonate OR pt cannot take an oral bisphosphonate because the pt cannot swallow or has difficulty swallowing or the pt cannot remain in an upright position post oral bisphosphonate administration or pt has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried an IV bisphosphonate (ibandronate or zoledronic acid), OR pt has severe renal impairment (creatinine clearance less than 35 mL/min) or CKD or pt has had an osteoporotic fracture or fragility fracture. Increase bone mass in men (a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression) with primary or hypogondal osteoporosis/Treatment of GIO, approve if pt tried one oral bisphosphonate OR pt cannot take an oral bisphosphonate because the patient cannot swallow or has difficulty swallowing or the patient cannot remain in an upright position post oral bisphosphonate administration or has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried zoledronic acid (Reclast), OR pt has severe renal impairment (CrCL less than 35 mL/min) or has CKD or has had an osteoporotic fracture or fragility fracture.

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

THALOMID

Products Affected

- THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 3 years.
Other Criteria	Erythem Nodosum Leprosum-approve. Multiple Myeloma-approve. Discoid lupus erythematosus or cutaneous lupus erythematosus, approve if the patient has tried at least two other therapies (eg, corticosteroids [oral, topical, intralesional], hydroxychloroquine, tacrolimus [Protopic], methotrexate, dapsone, acitretin [Soriatane]). Myelofibrosis, approve if according to the prescriber the patient has anemia and has serum erythropoietin levels greater than or equal to 500 mU/mL. Prurigo nodularis, approve. Recurrent aphthous ulcers or aphthous stomatitis, approve if the patient has tried at least two other therapies (eg, topical or intralesional corticosteroids, systemic corticosteroids, topical anesthetics/analgesics [eg, benzocaine lozenges], antimicrobial mouthwashes [eg, tetracycline], acyclovir, colchicine). AIDS Related Kaposi's Sarcoma-approve if the patient has tried at least one regimen or therapy and has relapsed or refractory disease. Castleman's disease-approve if the patient has multicentric Castleman's disease, is negative for the human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8) and has hyaline vascular histology.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Discoid lupus erythematosus or cutaneous lupus erythematosus, Myelofibrosis, Prurigo nodularis, Recurrent aphthous ulcers or aphthous

PA Criteria	Criteria Details
	stomatitis, AIDS related Kaposi's Sarcoma, Castleman's Disease.

TOPICAL AGENTS FOR ATOPIC DERMATITIS

Products Affected

- *tacrolimus topical*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	Authorize use in patients who have tried a prescription strength topical corticosteroid (brand or generic) for the current condition. Dermatologic condition on or around the eyes, eyelids, axilla, or genitalia, authorize use without a trial of a prescription strength topical corticosteroid.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

TOPICAL RETINOID PRODUCTS

Products Affected

- AVITA
- *tretinoin microspheres*
- *tretinoin topical*

PA Criteria	Criteria Details
Exclusion Criteria	Coverage is not provided for cosmetic use.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

TOPIRAMATE/ZONISAMIDE

Products Affected

- *topiramate oral capsule, sprinkle*
- *topiramate oral tablet*
- TROKENDI XR
- *zonisamide*

PA Criteria	Criteria Details
Exclusion Criteria	Coverage is not provided for weight loss or smoking cessation.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

TRACLEER

Products Affected

- *bosentan*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Pulmonary arterial hypertension (PAH) WHO Group 1, results of right heart cath
Age Restrictions	N/A
Prescriber Restrictions	For treatment of pulmonary arterial hypertension, ambrisentan or bosentan must be prescribed by or in consultation with a cardiologist or a pulmonologist. CTEPH-prescribed by or in consultation with a cardiologist or pulmonologist
Coverage Duration	Authorization will be for 1 year.
Other Criteria	CTEPH - pt must have tried Adempas, has a contraindication to Adempas, or is currently receiving bosentan for CTEPH. Pulmonary arterial hypertension (PAH) WHO Group 1, are required to have had a right-heart catheterization to confirm diagnosis of PAH to ensure appropriate medical assessment.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Chronic thromboembolic pulmonary hypertension (CTEPH) (bosentan)

TRANSMUCOSAL FENTANYL DRUGS

Products Affected

- *fentanyl citrate buccal lozenge on a handle*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	For breakthrough pain in patients with cancer if patient is unable to swallow, has dysphagia, esophagitis, mucositis, or uncontrollable nausea/vomiting OR patient is unable to take 2 other short-acting narcotics (eg, oxycodone, morphine sulfate, hydromorphone, etc) secondary to allergy or severe adverse events AND patient is on or will be on a long-acting narcotic (eg, Duragesic), or the patient is on intravenous, subcutaneous, or spinal (intrathecal, epidural) narcotics (eg, morphine sulfate, hydromorphone, fentanyl citrate). Clinical criteria incorporated into the quantity limit edits for all transmucosal fentanyl drugs require confirmation that the indication is breakthrough cancer pain (ie, FDA labeled use) prior to reviewing for quantity exception.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

TRELSTAR

Products Affected

- TRELSTAR INTRAMUSCULAR
SUSPENSION FOR RECONSTITUTION

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

TRIENTINE

Products Affected

- *trientine*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, medication history, pregnancy status, disease manifestations
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant physician.
Coverage Duration	Authorization will be for 3 years.
Other Criteria	For Wilson's Disease, approve if the patient meets ONE of the following: 1) Patient has tried a penicillamine product and per the prescribing physician the patient is intolerant to penicillamine therapy, OR 2) Per the prescribing physician, the patient has clinical features indicating the potential for intolerance to penicillamine therapy (ie, history of any renal disease, congestive splenomegaly causing severe thrombocytopenia, autoimmune tendency), OR 3) Per the prescribing physician, the patient has a contraindication to penicillamine therapy, OR 4) The patient has neurologic manifestations of Wilson's disease, OR 5) The patient is pregnant.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

TURALIO

Products Affected

- TURALIO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	3 years
Other Criteria	Tenosynovial Giant Cell Tumor (Pigmented Villonodular Synovitis)- approve if, according to the prescriber, the tumor is not amenable to improvement with surgery.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

TYMLOS

Products Affected

- TYMLOS

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other medications for osteoporosis (eg, denosumab [Prolia], bisphosphonates, calcitonin nasal spray [Fortical], Forteo), Evenity except calcium and Vitamin D. Previous use of Tymlos and/or teriparatide for a combined total no greater than 2 years duration during a patient's lifetime.
Required Medical Information	Previous medications tried, renal function
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 2 yrs of total therapy between Tymlos/teriparatide over a pt's lifetime.
Other Criteria	Treatment of PMO, approve if the patient meets ONE of the following criteria: patient has tried one oral bisphosphonate or cannot take an oral bisphosphonate because the patient cannot swallow or has difficulty swallowing or patient cannot remain in an upright position post oral bisphosphonate administration or patient has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR patient has tried an IV bisphosphonate (ibandronate or zoledronic acid), OR patient has severe renal impairment or CKD, OR patient has had an osteoporotic fracture or fragility fracture.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

TYSABRI

Products Affected

- TYSABRI

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use of other disease-modifying agents used for MS. Concurrent use with immunosuppressants (eg, 6-mercaptopurine, azathioprine, cyclosporine, methotrexate) in Crohn's disease (CD) patient
Required Medical Information	Diagnosis
Age Restrictions	18 and older (initial and continuation)
Prescriber Restrictions	MS: prescribed by, or in consultation with, a neurologist or a physician who specializes in the treatment of MS. (initial and continuation) CD: prescribed by, or in consultation with, a gastroenterologist (initial and continuation)
Coverage Duration	MS-Authorization will be for 1 year.CD, initial-3 mo. CD, cont therapy-1 year.
Other Criteria	Adults with a relapsing form of MS-initial. Patient has had an inadequate response to, or is unable to tolerate, one disease modifying agent used for MS: (eg, interferon beta-1a (Avonex, Rebif), interferon beta-1b (Betaseron, Extavia), glatiramer acetate (Copaxone/Glatopa), Plegridy, fingolimod (Gilenya), Tecfidera, Lemtrada, daclizumab (Zinbryta), Aubagio, Mavenclad, Mayzent, Vumerity, Lemtrada, Ocrevus) OR the patient has highly active or aggressive disease according to the prescribing physician by meeting one of the following-the patient has demonstrated rapidly-advancing deterioration(s) in physical functioning (e.g., loss of mobility/or lower levels of ambulation, severe changes in strength or coordination OR disabling relapse(s) with suboptimal response to systemic corticosteroids OR magnetic resonance imaging (MRI) findings suggest highly-active or aggressive multiple sclerosis (e.g., new, enlarging, or a high burden of T2 lesions or gadolinium lesions) OR manifestation of multiple sclerosis-related cognitive impairment. Adults with CD, initial. Patient has moderately to severely active CD and patient has tried two biologics for CD. CD, continuation therapy. Patient has had a response to Tysabri, as determined by the prescribing physician.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.

PA Criteria	Criteria Details
Off-Label Uses	Patients already started on Tysabri for a Covered Use.

UPTRAVI

Products Affected

- UPTRAVI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Confirmation of right heart catheterization, medication history.
Age Restrictions	N/A
Prescriber Restrictions	PAH must be prescribed by, or in consultation with, a cardiologist or a pulmonologist.
Coverage Duration	1 year
Other Criteria	Must have PAH (WHO Group 1) and had a right heart catheterization to confirm the diagnosis of PAH (WHO Group 1). Patient new to Uptravi therapy must meet a) OR b): a) tried TWO or is currently taking TWO oral therapies for PAH (either alone or in combination) each for 30 days, unless patient has experienced treatment failure, intolerance, or oral therapy is contraindicated: PDE5 inhibitor (eg, sildenafil, Revatio), endothelin receptor antagonist (ERA) [eg, Tracleer, Letairis or Opsumit], or Adempas, OR b) receiving or has received in the past one prostacyclin therapy for PAH (eg, Orenitram, Ventavis, or epoprostenol injection).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

VALTOCO

Products Affected

- VALTOCO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, other medications used at the same time
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	1 year
Other Criteria	Intermittent Episodes of Frequent Seizure Activity (i.e., seizure clusters, acute repetitive seizures)-approve if the patient is currently receiving maintenance antiepileptic medication(s).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

VANCOMYCIN

Products Affected

- *vancomycin oral capsule 125 mg, 250 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	2 weeks
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

VENTAVIS

Products Affected

- VENTAVIS

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	B vs D coverage determination
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

VERZENIO

Products Affected

- VERZENIO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	For use with an aromatase inhibitor in postmenopausal women or men as initial endocrine-based therapy, approve if the patient has tried Ibrance. For use with fulvestrant in patients with disease progression following endocrine therapy, approve if the patient has tried Ibrance.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

VIBERZI

Products Affected

- VIBERZI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis of irritable bowel syndrome with diarrhea.
Age Restrictions	18 years of age and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	The patient must have a history of failure, contraindication or intolerance to one antidiarrheal drug.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

VITRAKVI

Products Affected

- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, NTRK gene fusion status
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	3 years
Other Criteria	Solid tumors - approve if the tumor has a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation AND the tumor is metastatic or surgical resection of tumor will likely result in severe morbidity AND there are no satisfactory alternative treatments or the patient has disease progression following treatment.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

VOSEVI

Products Affected

- VOSEVI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Genotype, prescriber specialty, other medications tried or used in combination with requested medication
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician
Coverage Duration	Will be c/w AASLD guidance and inclusive of treatment already received for the requested drug
Other Criteria	Criteria will be applied consistent with current AASLD/IDSA guidance.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Indications consistent with current AASLD/IDSA guidance

XATMEP

Products Affected

- XATMEP

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

XCOPRI

Products Affected

- XCOPRI
- XCOPRI MAINTENANCE PACK
- XCOPRI TITRATION PACK

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve if the patient has tried one other anticonvulsant therapy (eg, carbamazepine, divalproex sodium, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, topiramate, valproic acid).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

XELJANZ

Products Affected

- XELJANZ
- XELJANZ XR

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with biologic therapy or targeted synthetic DMARD
Required Medical Information	Diagnosis, concurrent medications, previous drugs tried.
Age Restrictions	N/A
Prescriber Restrictions	RA, prescribed by or in consultation with a rheumatologist. PsA-prescribed by or in consultation with a rheumatologist or a dermatologist. UC-prescribed by or in consultation with a gastroenterologist.
Coverage Duration	PsA/RA-3 months initial, UC-16 weeks initial, All diagnoses-3 years cont.
Other Criteria	RA/PsA initial, patient has tried one conventional synthetic DMARD for at least 3 months (note: patients who have already had a 3-month trial of a biologic for RA are not required to step back and try a conventional synthetic DMARD). UC initial, approve if the patient has had a trial of one systemic agent for UC.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

XENAZINE

Products Affected

- *tetrabenazine oral tablet 12.5 mg, 25 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	For treatment of chorea associated with Huntington's disease, Tourette syndrome or related tic disorders, hyperkinetic dystonia, or hemiballism, must be prescribed by or after consultation with a neurologist. For TD, must be prescribed by or after consultation with a neurologist or psychiatrist.
Coverage Duration	Authorization will be for 1 year.
Other Criteria	N/A
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Tardive dyskinesia (TD). Tourette syndrome and related tic disorders. Hyperkinetic dystonia. Hemiballism.

XGEVA

Products Affected

- XGEVA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	For initial therapy in the treatment of hypercalcemia of malignancy: trial and failure, contraindication, or intolerance to one intravenous bisphosphonate (e.g. pamidronate, zoledronic acid) is required. For continuation of therapy in the treatment of hypercalcemia of malignancy, approve if patient has already been started on Xgeva. For other medically accepted indication, no trial of alternatives is required.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

XIAFLEX

Products Affected

- XIAFLEX

PA Criteria	Criteria Details
Exclusion Criteria	Retreatment (i.e., treatment beyond three injections per affected cord for those with Dupuytren's Contracture or beyond eight injections for Peyronie's Disease).
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Dupuytren's Contracture-administered by a healthcare provider experienced in injection procedures of the hand and in the treatment of Dupuytren's contracture. Peyronie's Disease -administered by a healthcare provider experienced in the treatment of male urological diseases.
Coverage Duration	Dupuytren's Contracture-3 months, Peyronie's Disease-6 months
Other Criteria	Dupuytren's Contracture-at baseline (prior to initial injection of Xiaflex), the patient had contracture of a metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint of at least 20 degrees AND the patient will not be treated with more than a total of three injections (maximum) per affected cord. Peyronie's Disease-the patient meets ONE of the following (i or ii): i. at baseline (prior to use of Xiaflex), the patient has a penile curvature deformity of at least 30 degrees OR in a patient who has received prior treatment with Xiaflex, the patient has a penile curvature deformity of at least 15 degrees AND the patient has not previously been treated with a complete course (8 injections) of Xiaflex for Peyronie's disease.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

XIFAXAN

Products Affected

- XIFAXAN ORAL TABLET 200 MG, 550 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A

XOLAIR

Products Affected

- XOLAIR SUBCUTANEOUS RECON SOLN
- XOLAIR SUBCUTANEOUS SYRINGE 150 MG/ML, 75 MG/0.5 ML

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with an Interleukin (IL) Antagonist Monoclonal Antibody
Required Medical Information	Moderate to severe persistent asthma, baseline IgE level of at least 30 IU/mL. For asthma, patient has a baseline positive skin test or in vitro testing (ie, a blood test for allergen-specific IgE antibodies such as an enzyme-linked immunoabsorbant assay (eg, immunoCAP, ELISA) or the RAST) for 1 or more perennial aeroallergens (eg, house dust mite, animal dander [dog, cat], cockroach, feathers, mold spores) and/or for 1 or more seasonal aeroallergens (grass, pollen, weeds).
Age Restrictions	Moderate to severe persistent asthma-6 years and older. All other diagnoses-12 years and older
Prescriber Restrictions	Moderate to severe persistent asthma if prescribed by, or in consultation with an allergist, immunologist, or pulmonologist. CIU if prescribed by or in consultation with an allergist, immunologist, or dermatologist.
Coverage Duration	Initial tx 4 months, continued tx 12 months
Other Criteria	Moderate to severe persistent asthma approve if pt meets criteria 1 and 2: 1) pt has received at least 3 months of combination therapy with an inhaled corticosteroid and at least one the following: long-acting beta-agonist (LABA), long-acting muscarinic antagonist (LAMA), leukotriene receptor antagonist, or theophylline, and 2) patient's asthma is uncontrolled or was uncontrolled prior to receiving any Xolair or anti-IL-4/13 therapy (Dupixent) therapy as defined by ONE of the following (a, b, c, d, or e): a) The patient experienced two or more asthma exacerbations requiring treatment with systemic corticosteroids in the previous year OR b) The patient experienced one or more asthma exacerbation requiring hospitalization or an Emergency Department (ED) visit in the previous year OR c) Patient has a forced expiratory volume in 1 second (FEV1) less than 80% predicted OR d) Patient has an FEV1/forced vital capacity (FVC) less than 0.80 OR e) The patient's asthma worsens upon tapering of oral corticosteroid therapy NOTE: An exception to the requirement for a trial of one additional asthma controller/maintenance medication can be made if

PA Criteria	Criteria Details
	<p>the patient has already received anti-IL-4/13 therapy (Dupixent) used concomitantly with an ICS for at least 3 consecutive months. For continued Tx for asthma - patient has responded to therapy as determined by the prescribing physician and continues to receive therapy with one inhaled corticosteroid or inhaled corticosteroid containing combination product. For CIU cont tx - must have responded to therapy as determined by the prescribing physician.</p>
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

XYREM

Products Affected

- XYREM

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Medication history
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by a sleep specialist physician or a Neurologist
Coverage Duration	12 months.
Other Criteria	For Excessive daytime sleepiness (EDS) in patients with narcolepsy - approve if the patient has tried two CNS stimulants (e.g., methylphenidate, dexamethylphenidate, dextroamphetamine), modafinil, or armodafinil and narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT). Cataplexy treatment in patients with narcolepsy- approve if narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

ZOLINZA

Products Affected

- ZOLINZA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	3 years
Other Criteria	Cutaneous T-Cell Lymphoma including Mycosis Fungoides/Sezary Syndrome-approve.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

ZYPREXA RELPREVV

Products Affected

- ZYPREXA RELPREVV RECONSTITUTION 210 MG, 300 MG,
INTRAMUSCULAR SUSPENSION FOR 405 MG

PA Criteria	Criteria Details
Exclusion Criteria	Dementia-related psychosis
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PART B VERSUS PART D

Products Affected

- *acetylcysteine solution 100 mg/ml (10 %), 200 mg/ml (20 %)*
- *acyclovir sodium intravenous solution 50 mg/ml*
- *adriamycin intravenous recon soln 10 mg*
- ADRIAMYCIN INTRAVENOUS RECON SOLN 50 MG
- *adriamycin intravenous solution 10 mg/5 ml, 2 mg/ml, 20 mg/10 ml, 50 mg/25 ml*
- *adrucil intravenous solution 2.5 gram/50 ml*
- *albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml, 5 mg/ml*
- AMINOSYN II 10 % INTRAVENOUS PARENTERAL SOLUTION 10 %
- AMINOSYN II 15 % INTRAVENOUS PARENTERAL SOLUTION 15 %
- AMINOSYN-PF 10 % INTRAVENOUS PARENTERAL SOLUTION 10 %
- AMINOSYN-PF 7 % (SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION 7 %
- *amiodarone intravenous solution 50 mg/ml*
- *aprepitant oral capsule 125 mg, 40 mg, 80 mg*
- *aprepitant oral capsule, dose pack 125 mg (1)- 80 mg (2)*
- ARRANON INTRAVENOUS SOLUTION 250 MG/50 ML
- ARSENIC TRIOXIDE INTRAVENOUS SOLUTION 1 MG/ML
- *arsenic trioxide intravenous solution 2 mg/ml*
- ARZERRA INTRAVENOUS SOLUTION 1,000 MG/50 ML, 100 MG/5 ML
- *azacitidine injection recon soln 100 mg*
- BELEODAQ INTRAVENOUS RECON SOLN 500 MG
- BENDEKA INTRAVENOUS SOLUTION 25 MG/ML
- BIVIGAM INTRAVENOUS SOLUTION 10 %
- *bleomycin injection recon soln 15 unit, 30 unit*
- BLINCYTO INTRAVENOUS KIT 35 MCG
- BROVANA INHALATION SOLUTION FOR NEBULIZATION 15 MCG/2 ML
- *budesonide inhalation suspension for nebulization 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/2 ml*
- *busulfan intravenous solution 60 mg/10 ml*
- BUSULFEX INTRAVENOUS SOLUTION 60 MG/10 ML
- *carboplatin intravenous solution 10 mg/ml*
- *carmustine intravenous recon soln 100 mg*
- *cisplatin intravenous solution 1 mg/ml*
- *cladribine intravenous solution 10 mg/10 ml*
- CLINIMIX 5%/D15W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION 5 %
- CLINIMIX 4.25%/D10W SULF FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 %
- CLINIMIX 4.25%/D5W SULFIT FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 %
- CLINIMIX 5%-D20W(SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION 5 %
- CLINIMIX E 4.25%/D10W SUL FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 %
- CLINISOL SF 15 % INTRAVENOUS PARENTERAL SOLUTION 15 %
- *clofarabine intravenous solution 20 mg/20 ml*
- COSMEGEN INTRAVENOUS RECON SOLN 0.5 MG

- *cromolyn inhalation solution for nebulization 20 mg/2 ml*
- *cyclophosphamide intravenous recon soln 1 gram, 2 gram, 500 mg*
- *cyclophosphamide oral capsule 25 mg, 50 mg*
- *cytarabine (pf) injection solution 100 mg/5 ml (20 mg/ml), 2 gram/20 ml (100 mg/ml), 20 mg/ml*
- *cytarabine injection solution 20 mg/ml*
- *dacarbazine intravenous recon soln 100 mg, 200 mg*
- *dactinomycin intravenous recon soln 0.5 mg*
- DARZALEX FASPRO SUBCUTANEOUS SOLUTION 1,800 MG-30,000 UNIT/15 ML
- *daunorubicin intravenous solution 5 mg/ml*
- *decitabine intravenous recon soln 50 mg*
- *docetaxel intravenous solution 160 mg/16 ml (10 mg/ml), 160 mg/8 ml (20 mg/ml), 20 mg/2 ml (10 mg/ml), 20 mg/ml (1 ml), 80 mg/4 ml (20 mg/ml), 80 mg/8 ml (10 mg/ml)*
- *doxorubicin intravenous recon soln 50 mg*
- *doxorubicin intravenous solution 10 mg/5 ml, 2 mg/ml, 20 mg/10 ml, 50 mg/25 ml*
- *doxorubicin, peg-liposomal intravenous suspension 2 mg/ml*
- *dronabinol oral capsule 10 mg, 2.5 mg, 5 mg*
- ELLENCE INTRAVENOUS SOLUTION 200 MG/100 ML, 50 MG/25 ML
- EMEND ORAL SUSPENSION FOR RECONSTITUTION 125 MG (25 MG/ML FINAL CONC.)
- ENGERIX-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/ML
- ENGERIX-B PEDIATRIC (PF) INTRAMUSCULAR SYRINGE 10 MCG/0.5 ML
- *epirubicin intravenous solution 200 mg/100 ml, 50 mg/25 ml*
- ERBITUX INTRAVENOUS SOLUTION 100 MG/50 ML, 200 MG/100 ML
- ERWINAZE INJECTION RECON SOLN 10,000 UNIT
- ETOPOPHOS INTRAVENOUS RECON SOLN 100 MG
- *etoposide intravenous solution 20 mg/ml*
- FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 120 MG, 80 MG
- FLEBOGAMMA DIF INTRAVENOUS SOLUTION 10 %
- *floxuridine injection recon soln 0.5 gram*
- *fludarabine intravenous recon soln 50 mg*
- *fludarabine intravenous solution 50 mg/2 ml*
- *fluorouracil intravenous solution 1 gram/20 ml, 2.5 gram/50 ml, 5 gram/100 ml, 500 mg/10 ml*
- FOLOTYN INTRAVENOUS SOLUTION 20 MG/ML (1 ML), 40 MG/2 ML (20 MG/ML)
- FREAMINE HBC 6.9 % INTRAVENOUS PARENTERAL SOLUTION 6.9 %
- *freamine iii 10 % intravenous parenteral solution 10 %*
- *fulvestrant intramuscular syringe 250 mg/5 ml*
- GAMMAGARD LIQUID INJECTION SOLUTION 10 %
- GAMMAGARD S-D (IGA < 1 MCG/ML) INTRAVENOUS RECON SOLN 10 GRAM, 5 GRAM
- GAMMAKED INJECTION SOLUTION 1 GRAM/10 ML (10 %), 10 GRAM/100 ML (10 %), 20 GRAM/200 ML (10 %), 5 GRAM/50 ML (10 %)
- GAMMAPLEX (WITH SORBITOL) INTRAVENOUS SOLUTION 5 %
- GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %), 10 GRAM/100 ML (10 %), 2.5 GRAM/25 ML (10 %), 20 GRAM/200 ML (10 %), 40 GRAM/400 ML (10 %), 5 GRAM/50 ML (10 %)
- *gemcitabine intravenous recon soln 1 gram, 2 gram, 200 mg*

- *gemcitabine intravenous solution 1 gram/26.3 ml (38 mg/ml), 2 gram/52.6 ml (38 mg/ml), 200 mg/5.26 ml (38 mg/ml)*
- GEMCITABINE INTRAVENOUS SOLUTION 100 MG/ML
- *granisetron (pf) intravenous solution 1 mg/ml (1 ml)*
- *granisetron hcl intravenous solution 1 mg/ml (1 ml)*
- *granisetron hcl oral tablet 1 mg*
- HEPATAMINE 8% INTRAVENOUS PARENTERAL SOLUTION 8 %
- HIZENTRA SUBCUTANEOUS SOLUTION 1 GRAM/5 ML (20 %), 10 GRAM/50 ML (20 %), 2 GRAM/10 ML (20 %), 4 GRAM/20 ML (20 %)
- HIZENTRA SUBCUTANEOUS SYRINGE 1 GRAM/5 ML (20 %), 2 GRAM/10 ML (20 %), 4 GRAM/20 ML (20 %)
- *idarubicin intravenous solution 1 mg/ml*
- *ifosfamide intravenous recon soln 1 gram, 3 gram*
- *ifosfamide intravenous solution 1 gram/20 ml, 3 gram/60 ml*
- INFUGEM INTRAVENOUS PIGGYBACK 1,200 MG/120 ML (10 MG/ML), 1,300 MG/130 ML (10 MG/ML), 1,400 MG/140 ML (10 MG/ML), 1,500 MG/150 ML (10 MG/ML), 1,600 MG/160 ML (10 MG/ML), 1,700 MG/170 ML (10 MG/ML), 1,800 MG/180 ML (10 MG/ML), 1,900 MG/190 ML (10 MG/ML), 2,000 MG/200 ML (10 MG/ML), 2,200 MG/220 ML (10 MG/ML)
- INFUMORPH P/F INJECTION SOLUTION 10 MG/ML, 25 MG/ML
- INTRALIPID INTRAVENOUS EMULSION 20 %, 30 %
- *ipratropium bromide inhalation solution 0.02 %*
- *ipratropium-albuterol inhalation solution for nebulization 0.5 mg-3 mg(2.5 mg base)/3 ml*
- *irinotecan intravenous solution 100 mg/5 ml, 300 mg/15 ml, 40 mg/2 ml, 500 mg/25 ml*
- IXEMPRA INTRAVENOUS RECON SOLN 15 MG, 45 MG
- JEVTANA INTRAVENOUS SOLUTION 10 MG/ML (FIRST DILUTION)
- KABIVEN INTRAVENOUS EMULSION 3.31-9.8-3.9 %
- KYPROLIS INTRAVENOUS RECON SOLN 10 MG, 30 MG, 60 MG
- *levalbuterol hcl inhalation solution for nebulization 0.31 mg/3 ml, 0.63 mg/3 ml, 1.25 mg/0.5 ml, 1.25 mg/3 ml*
- MARQIBO INTRAVENOUS KIT 5 MG/31 ML(0.16 MG/ML) FINAL
- *melphalan hcl intravenous recon soln 50 mg*
- *melphalan oral tablet 2 mg*
- *mesna intravenous solution 100 mg/ml*
- *mitomycin intravenous recon soln 20 mg, 40 mg, 5 mg*
- *mitoxantrone intravenous concentrate 2 mg/ml*
- MORPHINE INTRAVENOUS SYRINGE 10 MG/ML
- NEBUPENT INHALATION RECON SOLN 300 MG
- NEPHRAMINE 5.4 % INTRAVENOUS PARENTERAL SOLUTION 5.4 %
- NIPENT INTRAVENOUS RECON SOLN 10 MG
- *nitroglycerin intravenous solution 50 mg/10 ml (5 mg/ml)*
- NUTRILIPID INTRAVENOUS EMULSION 20 %
- OCTAGAM INTRAVENOUS SOLUTION 10 %, 5 %
- *ondansetron hcl oral solution 4 mg/5 ml*
- *ondansetron hcl oral tablet 24 mg, 4 mg, 8 mg*
- *ondansetron oral tablet, disintegrating 4 mg, 8 mg*
- *oxaliplatin intravenous recon soln 100 mg, 50 mg*

- *oxaliplatin intravenous solution 100 mg/20 ml, 50 mg/10 ml (5 mg/ml)*
- *paclitaxel intravenous concentrate 6 mg/ml*
- *palonosetron intravenous solution 0.25 mg/5 ml*
- *pentamidine inhalation recon soln 300 mg*
- PERFORMIST INHALATION SOLUTION FOR NEBULIZATION 20 MCG/2 ML
- PERIKABIVEN INTRAVENOUS EMULSION 2.36-6.8-3.5 %
- PLENAMINE INTRAVENOUS PARENTERAL SOLUTION 15 %
- PORTRAZZA INTRAVENOUS SOLUTION 800 MG/50 ML (16 MG/ML)
- *potassium chloride-d5-0.3%nacl intravenous parenteral solution 20 meq/l*
- PREMASOL 10 % INTRAVENOUS PARENTERAL SOLUTION 10 %
- PRIVIGEN INTRAVENOUS SOLUTION 10 %
- PROCALAMINE 3% INTRAVENOUS PARENTERAL SOLUTION 3 %
- PROLEUKIN INTRAVENOUS RECON SOLN 22 MILLION UNIT
- PROSOL 20 % INTRAVENOUS PARENTERAL SOLUTION
- PULMICORT INHALATION SUSPENSION FOR NEBULIZATION 0.25 MG/2 ML, 0.5 MG/2 ML, 1 MG/2 ML
- PULMOZYME INHALATION SOLUTION 1 MG/ML
- RECOMBIVAX HB (PF) INTRAMUSCULAR SUSPENSION 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5 ML
- RECOMBIVAX HB (PF) INTRAMUSCULAR SYRINGE 10 MCG/ML, 5 MCG/0.5 ML
- ROMIDEPSIN INTRAVENOUS SOLUTION 5 MG/ML
- SIMULECT INTRAVENOUS RECON SOLN 10 MG, 20 MG
- TEMODAR INTRAVENOUS RECON SOLN 100 MG
- *temsirolimus intravenous recon soln 30 mg/3 ml (10 mg/ml) (first)*
- *tobramycin in 0.225 % nacl inhalation solution for nebulization 300 mg/5 ml*
- *toposar intravenous solution 20 mg/ml*
- *topotecan intravenous solution 4 mg/4 ml (1 mg/ml)*
- TRAVASOL 10 % INTRAVENOUS PARENTERAL SOLUTION 10 %
- TREANDA INTRAVENOUS RECON SOLN 100 MG, 25 MG
- TRODELVY INTRAVENOUS RECON SOLN 180 MG
- TROPHAMINE 10 % INTRAVENOUS PARENTERAL SOLUTION 10 %
- TYVASO INHALATION SOLUTION FOR NEBULIZATION 1.74 MG/2.9 ML (0.6 MG/ML)
- TYVASO INSTITUTIONAL START KIT INHALATION SOLUTION FOR NEBULIZATION 1.74 MG/2.9 ML
- TYVASO REFILL KIT INHALATION SOLUTION FOR NEBULIZATION 1.74 MG/2.9 ML (0.6 MG/ML)
- TYVASO STARTER KIT INHALATION SOLUTION FOR NEBULIZATION 1.74 MG/2.9 ML
- *valrubicin intravesical solution 40 mg/ml*
- *vinblastine intravenous solution 1 mg/ml*
- *vincasar pfs intravenous solution 1 mg/ml, 2 mg/2 ml*
- *vincristine intravenous solution 1 mg/ml, 2 mg/2 ml*
- *vinorelbine intravenous solution 10 mg/ml, 50 mg/5 ml*
- VYXEOS INTRAVENOUS RECON SOLN 44-100 MG
- XOPENEX CONCENTRATE INHALATION SOLUTION FOR NEBULIZATION 1.25 MG/0.5 ML
- XOPENEX INHALATION SOLUTION FOR NEBULIZATION 0.31 MG/3 ML, 0.63 MG/3 ML, 1.25 MG/3 ML
- YUPELRI INHALATION SOLUTION FOR NEBULIZATION 175 MCG/3 ML

- ZALTRAP INTRAVENOUS SOLUTION 100 MG/4 ML (25 MG/ML), 200 MG/8 ML (25 MG/ML)
- ZANOSAR INTRAVENOUS RECON SOLN 1 GRAM
- ZOLADEX SUBCUTANEOUS IMPLANT 10.8 MG, 3.6 MG
- *zoledronic acid intravenous solution 4 mg/5 ml*
- *zoledronic acid-mannitol-water intravenous piggyback 4 mg/100 ml, 5 mg/100 ml*
- ZOLEDRONIC AC-MANNITOL-0.9NACL INTRAVENOUS PIGGYBACK 4 MG/100 ML

Details

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

Index

A

- ABELCET..... 12
- abiraterone..... 100, 101
- ABRAXANE 13, 14
- acetylcysteine solution 100 mg/ml (10 %),
200 mg/ml (20 %)..... 187
- ACTHAR..... 1
- ACTIMMUNE..... 2
- acyclovir sodium intravenous solution 50
mg/ml 187
- ADEMPAS 3
- adriamycin intravenous recon soln 10 mg
..... 187
- ADRIAMYCIN INTRAVENOUS RECON
SOLN 50 MG..... 187
- adriamycin intravenous solution 10 mg/5 ml,
2 mg/ml, 20 mg/10 ml, 50 mg/25 ml .. 187
- adrucil intravenous solution 2.5 gram/50 ml
..... 187
- AFINITOR DISPERZ ORAL TABLET
FOR SUSPENSION 2 MG, 3 MG, 5 MG
..... 100, 101
- AFINITOR ORAL TABLET 10 MG, 2.5
MG, 5 MG, 7.5 MG 100, 101
- AIMOVIG AUTOINJECTOR..... 4
- albuterol sulfate inhalation solution for
nebulization 0.63 mg/3 ml, 1.25 mg/3 ml,
2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml, 5
mg/ml 187
- ALDURAZYME..... 5
- ALECENSA..... 100, 101
- ALIMTA..... 13, 14
- ALIQOPA 13, 14
- alosetron..... 6
- ALUNBRIG ORAL TABLET 180 MG, 30
MG, 90 MG..... 100, 101
- ALUNBRIG ORAL TABLETS,DOSE
PACK..... 100, 101
- alyq..... 123
- AMBISOME 12
- ambrisentan 95
- amikacin injection solution 1,000 mg/4 ml,
500 mg/2 ml 9, 10
- AMINOSYN II 10 % INTRAVENOUS
PARENTERAL SOLUTION 10 % 187
- AMINOSYN II 15 % INTRAVENOUS
PARENTERAL SOLUTION 15 % 187
- AMINOSYN-PF 10 % INTRAVENOUS
PARENTERAL SOLUTION 10 % 187
- AMINOSYN-PF 7 % (SULFITE-FREE)
INTRAVENOUS PARENTERAL
SOLUTION 7 % 187
- amiodarone intravenous solution 50 mg/ml
..... 187
- amphotericin b 12
- ampicillin sodium..... 9, 10
- ampicillin-sulbactam..... 9, 10
- ANADROL-50..... 8
- APOKYN..... 15
- aprepitant oral capsule 125 mg, 40 mg, 80
mg 187
- aprepitant oral capsule,dose pack 125 mg
(1)- 80 mg (2)..... 187
- ARANESP (IN POLYSORBATE)
INJECTION SOLUTION 100 MCG/ML,
200 MCG/ML, 25 MCG/ML, 300
MCG/ML, 40 MCG/ML, 60 MCG/ML 16
- ARANESP (IN POLYSORBATE)
INJECTION SYRINGE..... 16
- ARCALYST 17
- ARIKAYCE..... 18
- armodafinil..... 111
- ARRANON INTRAVENOUS SOLUTION
250 MG/50 ML..... 187
- ARSENIC TRIOXIDE INTRAVENOUS
SOLUTION 1 MG/ML 187
- arsenic trioxide intravenous solution 2
mg/ml 187
- ARZERRA INTRAVENOUS SOLUTION
1,000 MG/50 ML, 100 MG/5 ML 187
- ascomp with codeine..... 77
- ASTAGRAF XL 84
- ATGAM 84
- AUBAGIO 20
- AURYXIA 21
- AUSTEDO ORAL TABLET 12 MG, 6 MG,
9 MG 22
- AVITA 157
- AVONEX INTRAMUSCULAR PEN
INJECTOR KIT 23

AVONEX INTRAMUSCULAR SYRINGE KIT	23	BUSULFEX INTRAVENOUS SOLUTION 60 MG/10 ML	187
AYVAKIT	100, 101	butalbital compound w/codeine	77
azacitidine injection recon soln 100 mg..	187	butalbital-acetaminop-caf-cod	77
AZASAN	84	butalbital-acetaminophen oral tablet 50-300 mg, 50-325 mg	77
azathioprine	84	butalbital-acetaminophen-caff oral capsule	77
azathioprine sodium	84	butalbital-acetaminophen-caff oral tablet 50- 325-40 mg	77
azithromycin intravenous	9, 10	butalbital-aspirin-caffeine oral capsule.....	77
aztreonam	9, 10	C	
B		CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG	100, 101
BALVERSA	100, 101	CALQUENCE	100, 101
BAVENCIO	13, 14	CAPLYTA	29
BELEODAQ INTRAVENOUS RECON SOLN 500 MG	187	CAPRELSA ORAL TABLET 100 MG, 300 MG	100, 101
BENDEKA INTRAVENOUS SOLUTION 25 MG/ML	187	CARBAGLU	30
BENLYSTA INTRAVENOUS RECON SOLN 120 MG, 400 MG	24	carboplatin intravenous solution 10 mg/ml	187
BENLYSTA SUBCUTANEOUS	24	carisoprodol	72
benztropine oral	71	carisoprodol-aspirin	80
BESPONSA	13, 14	carisoprodol-aspirin-codeine	80
BETASERON SUBCUTANEOUS KIT ..	25	carmustine intravenous recon soln 100 mg	187
bexarotene	149	casprofungin	11
BICILLIN L-A	9, 10	CAYSTON	31
BIVIGAM INTRAVENOUS SOLUTION 10 %	187	cefazolin in dextrose (iso-os) intravenous piggyback 1 gram/50 ml	9, 10
bleomycin injection recon soln 15 unit, 30 unit	187	cefazolin injection recon soln 100 gram, 300 g	9, 10
BLINCYTO INTRAVENOUS KIT 35 MCG	187	cefazolin intravenous	9, 10
BORTEZOMIB	13, 14	CEFEPIME IN DEXTROSE 5 %	9, 10
bosentan	159	cefepime in dextrose, iso-osm	9, 10
BOSULIF	100, 101	cefotaxime injection recon soln 1 gram 9, 10	
BOTOX	26, 27	CEFOTETAN IN DEXTROSE, ISO-OSM9, 10	
BRAFTOVI ORAL CAPSULE 75 MG 100, 101		cefotetan injection	9, 10
BROVANA INHALATION SOLUTION FOR NEBULIZATION 15 MCG/2 ML	187	cefoxitin	9, 10
BRUKINSA	100, 101	cefoxitin in dextrose, iso-osm	9, 10
budesonide inhalation suspension for nebulization 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/2 ml	187	ceftazidime	9, 10
bupap oral tablet 50-300 mg	77	CEFTAZIDIME IN D5W	9, 10
busulfan intravenous solution 60 mg/10 ml	187	ceftriaxone in dextrose, iso-os	9, 10
		CEFTRIAZONE INJECTION RECON SOLN 100 GRAM	9, 10

ceftriaxone intravenous.....	9, 10	COMETRIQ ORAL CAPSULE 100	
cefuroxime sodium injection recon soln 750		MG/DAY(80 MG X1-20 MG X1), 140	
mg	9, 10	MG/DAY(80 MG X1-20 MG X3), 60	
cefuroxime sodium intravenous.....	9, 10	MG/DAY (20 MG X 3/DAY).....	100, 101
CELLCEPT.....	84	COPAXONE SUBCUTANEOUS	
CEREZYME INTRAVENOUS RECON		SYRINGE 20 MG/ML, 40 MG/ML	37
SOLN 400 UNIT.....	32	COPIKTRA.....	100, 101
CHEMET	33	CORLANOR ORAL TABLET	38
chlorzoxazone oral tablet 500 mg.....	80	COSMEGEN INTRAVENOUS RECON	
CHORIONIC GONADOTROPIN,		SOLN 0.5 MG.....	187
HUMAN INTRAMUSCULAR.....	34	COTELLIC	100, 101
CIALIS ORAL TABLET 2.5 MG, 5 MG.	35	CRINONE VAGINAL GEL 8 %	39
ciprofloxacin in 5 % dextrose	9, 10	cromolyn inhalation solution for	
cisplatin intravenous solution 1 mg/ml... 187		nebulization 20 mg/2 ml	188
cladribine intravenous solution 10 mg/10 ml		cyclobenzaprine oral tablet 10 mg, 5 mg..	73
.....	187	cyclobenzaprine oral tablet 7.5 mg.....	80
CLINDAMYCIN IN 0.9 % SOD CHLOR 9,		cyclophosphamide intravenous recon soln 1	
10		gram, 2 gram, 500 mg.....	188
clindamycin in 5 % dextrose.....	9, 10	cyclophosphamide oral capsule 25 mg, 50	
clindamycin phosphate injection.....	9, 10	mg	188
clindamycin phosphate intravenous solution		cyclosporine intravenous	84
600 mg/4 ml.....	9, 10	cyclosporine modified.....	84
CLINIMIX 5%/D15W SULFITE FREE		cyclosporine oral capsule.....	84
INTRAVENOUS PARENTERAL		CYRAMZA.....	13, 14
SOLUTION 5 %.....	187	CYSTARAN.....	40
CLINIMIX 4.25%/D10W SULF FREE		cytarabine (pf) injection solution 100 mg/5	
INTRAVENOUS PARENTERAL		ml (20 mg/ml), 2 gram/20 ml (100	
SOLUTION 4.25 %	187	mg/ml), 20 mg/ml	188
CLINIMIX 4.25%/D5W SULFIT FREE		cytarabine injection solution 20 mg/ml... 188	
INTRAVENOUS PARENTERAL		D	
SOLUTION 4.25 %	187	dacarbazine intravenous recon soln 100 mg,	
CLINIMIX 5%-D20W(SULFITE-FREE)		200 mg	188
INTRAVENOUS PARENTERAL		dactinomycin intravenous recon soln 0.5 mg	
SOLUTION 5 %	187	188
CLINIMIX E 4.25%/D10W SUL FREE		dalfampridine	7
INTRAVENOUS PARENTERAL		DARZALEX.....	13, 14
SOLUTION 4.25 %	187	DARZALEX FASPRO SUBCUTANEOUS	
CLINISOL SF 15 % INTRAVENOUS		SOLUTION 1,800 MG-30,000 UNIT/15	
PARENTERAL SOLUTION 15 %	187	ML.....	188
clobazam oral suspension	36	daunorubicin intravenous solution 5 mg/ml	
clobazam oral tablet.....	36	188
clofarabine intravenous solution 20 mg/20		DAURISMO ORAL TABLET 100 MG, 25	
ml	187	MG	100, 101
codeine-butalbital-asa-caff.....	77	decitabine intravenous recon soln 50 mg 188	
COLISTIN (COLISTIMETHATE NA) 9, 10		DEMSER	122
		DIFICID	42

docetaxel intravenous solution 160 mg/16 ml (10 mg/ml), 160 mg/8 ml (20 mg/ml), 20 mg/2 ml (10 mg/ml), 20 mg/ml (1 ml), 80 mg/4 ml (20 mg/ml), 80 mg/8 ml (10 mg/ml).....	188	epirubicin intravenous solution 200 mg/100 ml, 50 mg/25 ml.....	188
doxorubicin intravenous recon soln 50 mg	188	EPOGEN INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML	51, 52
doxorubicin intravenous solution 10 mg/5 ml, 2 mg/ml, 20 mg/10 ml, 50 mg/25 ml	188	ERBITUX INTRAVENOUS SOLUTION 100 MG/50 ML, 200 MG/100 ML	188
doxorubicin, peg-liposomal intravenous suspension 2 mg/ml.....	188	ergoloid	76
doxy-100	9, 10	ERIVEDGE.....	53
dronabinol oral capsule 10 mg, 2.5 mg, 5 mg	188	ERLEADA	54
DUAVEE	43	erlotinib oral tablet 100 mg, 150 mg, 25 mg	100, 101
DUPIXENT SYRINGE	44, 45	ERWINAZE INJECTION RECON SOLN 10,000 UNIT	188
E		ERYTHROCIN INTRAVENOUS RECON SOLN 500 MG.....	9, 10
ELAPRASE	46	ESBRIET ORAL CAPSULE.....	55
ELIGARD	65	ESBRIET ORAL TABLET 267 MG, 801 MG	55
ELIGARD (3 MONTH).....	65	ETOPOPHOS INTRAVENOUS RECON SOLN 100 MG.....	188
ELIGARD (4 MONTH).....	65	etoposide intravenous solution 20 mg/ml	188
ELIGARD (6 MONTH).....	65	everolimus (antineoplastic).....	100, 101
ELLECE INTRAVENOUS SOLUTION 200 MG/100 ML, 50 MG/25 ML	188	everolimus (immunosuppressive) oral tablet 0.25 mg, 0.5 mg, 0.75 mg	84
ELZONRIS	13, 14	EVOMELA	13, 14
EMEND ORAL SUSPENSION FOR RECONSTITUTION 125 MG (25 MG/ ML FINAL CONC.)	188	EXTAVIA.....	56
EMPLICITI.....	13, 14	EYLEA	57
ENBREL MINI.....	47, 48	F	
ENBREL SUBCUTANEOUS RECON SOLN	47, 48	FANAPT ORAL TABLET.....	19
ENBREL SUBCUTANEOUS SYRINGE	47, 48	FANAPT ORAL TABLETS,DOSE PACK	19
48		FARYDAK ORAL CAPSULE 10 MG, 15 MG, 20 MG.....	100, 101
ENBREL SURECLICK.....	47, 48	fentanyl citrate buccal lozenge on a handle	160
ENGERIX-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/ML	188	FERRIPROX.....	58
ENGERIX-B PEDIATRIC (PF) INTRAMUSCULAR SYRINGE 10 MCG/0.5 ML	188	FIRDAPSE.....	60
ENHERTU	13, 14	FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 120 MG, 80 MG.....	188
ENVARBUS XR.....	84	FLEBOGAMMA DIF INTRAVENOUS SOLUTION 10 %	188
EPCLUSA.....	49	floxuridine injection recon soln 0.5 gram	188
EPIDIOLEX.....	50		

fluconazole in nacl (iso-osm) intravenous piggyback 200 mg/100 ml, 400 mg/200 ml 11
 fludarabine intravenous recon soln 50 mg 188
 fludarabine intravenous solution 50 mg/2 ml 188
 fluorouracil intravenous solution 1 gram/20 ml, 2.5 gram/50 ml, 5 gram/100 ml, 500 mg/10 ml 188
FOLOTYN INTRAVENOUS SOLUTION 20 MG/ML (1 ML), 40 MG/2 ML (20 MG/ML)..... 188
FORTEO..... 61, 62
FREAMINE HBC 6.9 % INTRAVENOUS PARENTERAL SOLUTION 6.9 % ... 188
 freamine iii 10 % intravenous parenteral solution 10 % 188
 fulvestrant intramuscular syringe 250 mg/5 ml 188
G
GAMMAGARD LIQUID INJECTION SOLUTION 10 % 188
GAMMAGARD S-D (IGA < 1 MCG/ML) INTRAVENOUS RECON SOLN 10 GRAM, 5 GRAM..... 188
GAMMAKED INJECTION SOLUTION 1 GRAM/10 ML (10 %), 10 GRAM/100 ML (10 %), 20 GRAM/200 ML (10 %), 5 GRAM/50 ML (10 %) 188
GAMMAPLEX (WITH SORBITOL) INTRAVENOUS SOLUTION 5 %.... 188
GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %), 10 GRAM/100 ML (10 %), 2.5 GRAM/25 ML (10 %), 20 GRAM/200 ML (10 %), 40 GRAM/400 ML (10 %), 5 GRAM/50 ML (10 %)..... 188
GATTEX 30-VIAL..... 63
GATTEX ONE-VIAL 63
GAZYVA..... 13, 14
 gemcitabine intravenous recon soln 1 gram, 2 gram, 200 mg 188
 gemcitabine intravenous solution 1 gram/26.3 ml (38 mg/ml), 2 gram/52.6 ml

(38 mg/ml), 200 mg/5.26 ml (38 mg/ml) 189
GEMCITABINE INTRAVENOUS SOLUTION 100 MG/ML 189
 gengraf oral capsule 100 mg, 25 mg 84
 gengraf oral solution 84
GENOTROPIN 66, 67
GENOTROPIN MINIQUICK 66, 67
 gentamicin in nacl (iso-osm) intravenous piggyback 100 mg/100 ml, 60 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml..... 9, 10
GENTAMICIN IN NAACL (ISO-OSM) INTRAVENOUS PIGGYBACK 100 MG/50 ML, 120 MG/100 ML 9, 10
 gentamicin injection solution 40 mg/ml 9, 10
 gentamicin sulfate (ped) (pf)..... 9, 10
GILENYA ORAL CAPSULE 0.5 MG.... 64
GILOTRIF 100, 101
 glyburide 78
 glyburide micronized 78
 glyburide-metformin 79
 granisetron (pf) intravenous solution 1 mg/ml (1 ml) 189
 granisetron hcl intravenous solution 1 mg/ml (1 ml)..... 189
 granisetron hcl oral tablet 1 mg 189
H
HAEGARDA 28
HALAVEN 68
HARVONI ORAL PELLETS IN PACKET 33.75-150 MG, 45-200 MG 69
HARVONI ORAL TABLET 45-200 MG, 90-400 MG..... 69
HEPATAMINE 8% INTRAVENOUS PARENTERAL SOLUTION 8 % 189
HETLIOZ..... 70
HIZENTRA SUBCUTANEOUS SOLUTION 1 GRAM/5 ML (20 %), 10 GRAM/50 ML (20 %), 2 GRAM/10 ML (20 %), 4 GRAM/20 ML (20 %) 189
HIZENTRA SUBCUTANEOUS SYRINGE 1 GRAM/5 ML (20 %), 2 GRAM/10 ML (20 %), 4 GRAM/20 ML (20 %) 189
HUMIRA PEN..... 82, 83
HUMIRA PEN CROHNS-UC-HS START 82, 83

HUMIRA PEN PSOR-UVEITS-ADOL HS	82, 83	MG/ML), 2,200 MG/220 ML (10 MG/ML).....	189
HUMIRA SUBCUTANEOUS SYRINGE KIT 10 MG/0.2 ML, 20 MG/0.4 ML, 40 MG/0.8 ML.....	82, 83	INFUMORPH P/F INJECTION SOLUTION 10 MG/ML, 25 MG/ML	189
HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML.....	82, 83	INLYTA ORAL TABLET 1 MG, 5 MG	100, 101
HUMIRA(CF) PEN CROHNS-UC-HS... 82, 83		INREBIC.....	100, 101
HUMIRA(CF) PEN PSOR-UV-ADOL HS	82, 83	INTRALIPID INTRAVENOUS EMULSION 20 %, 30 %	189
HUMIRA(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML. 82, 83		INTRAROSA.....	89
HUMIRA(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML	82, 83	ipratropium bromide inhalation solution 0.02 %	189
I		ipratropium-albuterol inhalation solution for nebulization 0.5 mg-3 mg(2.5 mg base)/3 ml	189
IBRANCE.....	100, 101	IRESSA.....	100, 101
icatibant.....	59	irinotecan intravenous solution 100 mg/5 ml, 300 mg/15 ml, 40 mg/2 ml, 500 mg/25 ml	189
ICLUSIG ORAL TABLET 15 MG, 45 MG	100, 101	IXEMPRA INTRAVENOUS RECON SOLN 15 MG, 45 MG	189
idarubicin intravenous solution 1 mg/ml	189	J	
IDHIFA.....	100, 101	JAKAFI.....	100, 101
ifosfamide intravenous recon soln 1 gram, 3 gram	189	JEVTANA INTRAVENOUS SOLUTION 10 MG/ML (FIRST DILUTION)	189
ifosfamide intravenous solution 1 gram/20 ml, 3 gram/60 ml.....	189	K	
imatinib oral tablet 100 mg, 400 mg	100, 101	KABIVEN INTRAVENOUS EMULSION 3.31-9.8-3.9 %.....	189
IMBRUVICA ORAL CAPSULE 140 MG, 70 MG	100, 101	KADCYLA.....	13, 14
IMBRUVICA ORAL TABLET	100, 101	KALYDECO ORAL GRANULES IN PACKET.....	90
IMFINZI.....	13, 14	KALYDECO ORAL TABLET	90
INCRELEX.....	85	KANJINTI	13, 14
INFUGEM INTRAVENOUS PIGGYBACK 1,200 MG/120 ML (10 MG/ML), 1,300 MG/130 ML (10 MG/ML), 1,400 MG/140 ML (10 MG/ML), 1,500 MG/150 ML (10 MG/ML), 1,600 MG/160 ML (10 MG/ML), 1,700 MG/170 ML (10 MG/ML), 1,800 MG/180 ML (10 MG/ML), 1,900 MG/190 ML (10 MG/ML), 2,000 MG/200 ML (10		KEYTRUDA INTRAVENOUS SOLUTION.....	13, 14
		KINERET	91
		KISQALI FEMARA CO-PACK ORAL TABLET 200 MG/DAY(200 MG X 1)- 2.5 MG, 400 MG/DAY(200 MG X 2)-2.5 MG, 600 MG/DAY(200 MG X 3)-2.5 MG	92
		KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3).....	92
		KORLYM	93
		KUVAN	94

KYPROLIS INTRAVENOUS RECON
SOLN 10 MG, 30 MG, 60 MG..... 189

L

LENVIMA ORAL CAPSULE 10 MG/DAY
(10 MG X 1), 12 MG/DAY (4 MG X 3),
14 MG/DAY(10 MG X 1-4 MG X 1), 18
MG/DAY (10 MG X 1-4 MG X2), 20
MG/DAY (10 MG X 2), 24 MG/DAY(10
MG X 2-4 MG X 1), 4 MG, 8 MG/DAY
(4 MG X 2)..... 100, 101

leuprolide subcutaneous kit..... 65

levabuterol hcl inhalation solution for
nebulization 0.31 mg/3 ml, 0.63 mg/3 ml,
1.25 mg/0.5 ml, 1.25 mg/3 ml..... 189

levofloxacin in d5w..... 9, 10

levofloxacin intravenous..... 9, 10

LIBTAYO..... 13, 14

lincomycin..... 9, 10

linezolid in dextrose 5%..... 9, 10

linezolid-0.9% sodium chloride..... 9, 10

LONSURF ORAL TABLET 15-6.14 MG,
20-8.19 MG..... 100, 101

LORBRENA ORAL TABLET 100 MG, 25
MG..... 100, 101

LUMIZYME..... 96

LUMOXITI..... 13, 14

LUPRON DEPOT..... 65

LUPRON DEPOT (3 MONTH)..... 65

LUPRON DEPOT (4 MONTH)..... 65

LUPRON DEPOT (6 MONTH)..... 65

LUPRON DEPOT-PED (3 MONTH)
INTRAMUSCULAR SYRINGE KIT
11.25 MG, 30 MG..... 65

LUPRON DEPOT-PED
INTRAMUSCULAR KIT 11.25 MG, 15
MG, 7.5 MG (PED)..... 65

LYNPARZA ORAL TABLET..... 100, 101

M

MARQIBO INTRAVENOUS KIT 5 MG/31
ML(0.16 MG/ML) FINAL..... 189

MAVYRET..... 97

megestrol oral suspension 400 mg/10 ml (10
ml), 400 mg/10 ml (40 mg/ml), 625 mg/5
ml (125 mg/ml)..... 98

megestrol oral tablet..... 98

MEKINIST ORAL TABLET 0.5 MG, 2
MG..... 100, 101

MEKTOVI..... 100, 101

melphalan hcl intravenous recon soln 50 mg
..... 189

melphalan oral tablet 2 mg..... 189

memantine oral capsule,sprinkle,er 24hr 105

memantine oral solution..... 105

memantine oral tablet 10 mg, 5 mg 105

memantine oral tablets,dose pack 105

mesna intravenous solution 100 mg/ml .. 189

metaxalone 80

methamphetamine 99

methocarbamol oral 80

metro i.v. 9, 10

metronidazole in nacl (iso-os)..... 9, 10

mitomycin intravenous recon soln 20 mg, 40
mg, 5 mg 189

mitoxantrone intravenous concentrate 2
mg/ml 189

modafinil oral tablet 100 mg, 200 mg..... 111

MORPHINE INTRAVENOUS SYRINGE
10 MG/ML..... 189

MOXIFLOXACIN-SOD.ACE,SUL-
WATER 9, 10

moxifloxacin-sod.chloride(iso)..... 9, 10

MVASI..... 13, 14

mycophenolate mofetil..... 84

mycophenolate mofetil (hcl)..... 84

mycophenolate sodium 84

MYFORTIC..... 84

MYLOTARG..... 13, 14

N

nafcillin 9, 10

nafcillin in dextrose iso-osm..... 9, 10

NAGLAZYME 102

NAMZARIC 105

NATPARA..... 103

NAYZILAM 104

NEBUPENT INHALATION RECON
SOLN 300 MG..... 189

NEORAL 84

NEPHRAMINE 5.4 % INTRAVENOUS
PARENTERAL SOLUTION 5.4 % ... 189

NERLYNX 100, 101

NEXAVAR..... 100, 101

NINLARO..... 100, 101
 NIPENT INTRAVENOUS RECON SOLN
 10 MG 189
 nitroglycerin intravenous solution 50 mg/10
 ml (5 mg/ml) 189
 NORTHERA ORAL CAPSULE 100 MG,
 200 MG, 300 MG..... 106
 NOVAREL 34
 NUBEQA..... 107
 NUEDEXTA..... 108
 NULOJIX..... 109
 NUPLAZID ORAL CAPSULE 110
 NUPLAZID ORAL TABLET 10 MG 110
 NUTRILIPID INTRAVENOUS
 EMULSION 20 %..... 189
 NUZYRA INTRAVENOUS 9, 10
O
 OCALIVA..... 112
 OCREVUS..... 113
 OCTAGAM INTRAVENOUS SOLUTION
 10 %, 5 %..... 189
 octreotide acetate 114
 ODOMZO 115
 OFEV 116
 OGIVRI..... 13, 14
 ondansetron hcl oral solution 4 mg/5 ml. 189
 ondansetron hcl oral tablet 24 mg, 4 mg, 8
 mg 189
 ondansetron oral tablet,disintegrating 4 mg,
 8 mg 189
 ONIVYDE 13, 14
 OPDIVO 13, 14
 OPSUMIT 117
 ORBACTIV 9, 10
 ORENCIA CLICKJECT..... 118
 ORENCIA SUBCUTANEOUS SYRINGE
 125 MG/ML, 50 MG/0.4 ML, 87.5
 MG/0.7 ML 118
 ORKAMBI ORAL GRANULES IN
 PACKET 119
 ORKAMBI ORAL TABLET 119
 orphenadrine citrate oral 80
 OSPHENA 120
 oxacillin injection..... 9, 10
 oxaliplatin intravenous recon soln 100 mg,
 50 mg 189

oxaliplatin intravenous solution 100 mg/20
 ml, 50 mg/10 ml (5 mg/ml)..... 190
 oxandrolone oral tablet 10 mg, 2.5 mg 8
P
 paclitaxel intravenous concentrate 6 mg/ml
 190
 PADCEV..... 13, 14
 paliperidone oral tablet extended release
 24hr 1.5 mg, 3 mg, 6 mg, 9 mg..... 19
 palonosetron intravenous solution 0.25 mg/5
 ml 190
 PEMAZYRE 100, 101
 penicillin g potassium 9, 10
 pentamidine inhalation recon soln 300 mg
 190
 PERFORMIST INHALATION
 SOLUTION FOR NEBULIZATION 20
 MCG/2 ML 190
 PERIKABIVEN INTRAVENOUS
 EMULSION 2.36-6.8-3.5 %..... 190
 PERJETA 13, 14
 pfizerpen-g 9, 10
 phenobarbital oral elixir 75
 phenobarbital oral tablet 75
 PIPERACILLIN-TAZOBACTAM
 INTRAVENOUS RECON SOLN 13.5
 GRAM..... 9, 10
 PIQRAY 100, 101
 PLENAMINE INTRAVENOUS
 PARENTERAL SOLUTION 15 % 190
 POLIVY 13, 14
 polymyxin b sulfate..... 9, 10
 POMALYST 100, 101
 PORTRAZZA INTRAVENOUS
 SOLUTION 800 MG/50 ML (16
 MG/ML)..... 190
 potassium chloride-d5-0.3%nacl intravenous
 parenteral solution 20 meq/l..... 190
 POTELIGEO..... 13, 14
 PREGNYL 34
 PREMASOL 10 % INTRAVENOUS
 PARENTERAL SOLUTION 10 % 190
 PRIVIGEN INTRAVENOUS SOLUTION
 10 % 190
 PROCALAMINE 3% INTRAVENOUS
 PARENTERAL SOLUTION 3 % 190

PROCRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML, 40,000 UNIT/ML.....	51, 52	REPATHA	130, 131
PROGRAF	84	REPATHA PUSHTRONEX.....	130, 131
PROLASTIN-C.....	124	REPATHA SURECLICK.....	130, 131
PROLEUKIN INTRAVENOUS RECON SOLN 22 MILLION UNIT.....	190	RETACRIT	51, 52
PROMACTA ORAL POWDER IN PACKET 12.5 MG, 25 MG	125, 126	RETEVMO	100, 101
PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG	125, 126	REVLIMID	132
promethazine oral.....	74	RINVOQ.....	134
PROSOL 20 % INTRAVENOUS PARENTERAL SOLUTION.....	190	ROMIDEPSIN INTRAVENOUS SOLUTION 5 MG/ML.....	190
PULMICORT INHALATION SUSPENSION FOR NEBULIZATION 0.25 MG/2 ML, 0.5 MG/2 ML, 1 MG/2 ML.....	190	ROZLYTREK ORAL CAPSULE 100 MG, 200 MG	135
PULMOZYME INHALATION SOLUTION 1 MG/ML.....	190	RUBRACA	100, 101
pyrimethamine	127	RUXIENCE	13, 14
Q		RYDAPT.....	100, 101
QINLOCK.....	100, 101	S	
R		SAMSCA ORAL TABLET 15 MG, 30 MG	136
RAPAMUNE	84	SANDIMMUNE ORAL SOLUTION	84
REBIF (WITH ALBUMIN)	128	SANDOSTATIN LAR DEPOT INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON.....	137
REBIF REBIDOSE SUBCUTANEOUS PEN INJECTOR 22 MCG/0.5 ML, 44 MCG/0.5 ML, 8.8MCG/0.2ML-22 MCG/0.5ML (6).....	128	SARCLISA	13, 14
REBIF TITRATION PACK	128	SIGNIFOR	138
RECOMBIVAX HB (PF) INTRAMUSCULAR SUSPENSION 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5 ML	190	sildenafil (pulmonary arterial hypertension) oral tablet	123
RECOMBIVAX HB (PF) INTRAMUSCULAR SYRINGE 10 MCG/ML, 5 MCG/0.5 ML	190	SIMULECT INTRAVENOUS RECON SOLN 10 MG, 20 MG	190
REGANEX.....	41	sirolimus.....	84
RELISTOR SUBCUTANEOUS SOLUTION.....	129	SIRTURO ORAL TABLET 100 MG.....	139
RELISTOR SUBCUTANEOUS SYRINGE	129	SIVEXTRO INTRAVENOUS	9, 10
RENFLEXIS	86, 87, 88	SKYRIZI SUBCUTANEOUS SYRINGE KIT	140
		sodium phenylbutyrate.....	121
		SOMATULINE DEPOT.....	141
		SOMAVERT.....	142
		SPRYCEL ORAL TABLET 100 MG, 140 MG, 20 MG, 50 MG, 70 MG, 80 MG 100, 101	
		STELARA INTRAVENOUS	143
		STELARA SUBCUTANEOUS SOLUTION.....	143
		STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML	143
		STIVARGA	100, 101
		STREPTOMYCIN	9, 10

sulfamethoxazole-trimethoprim intravenous	9, 10
SUTENT	100, 101
SYLATRON SUBCUTANEOUS KIT 200 MCG, 300 MCG	144
SYMDEKO	145
SYMLINPEN 120	146
SYMLINPEN 60	146
SYMPAZAN	36
SYNAGIS	147
SYNERCID	9, 10
SYNRIBO	100, 101
T	
TABRECTA	100, 101
tacrolimus oral	84
tacrolimus topical	156
tadalafil (pulm. hypertension)	123
tadalafil oral tablet 2.5 mg, 5 mg	35
TAFINLAR	100, 101
TAGRISSE	100, 101
TALTZ SYRINGE	148
TALZENNA ORAL CAPSULE 0.25 MG, 1 MG	100, 101
TARGRETIN TOPICAL	150
TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG	100, 101
tazicef	9, 10
TAZVERIK	100, 101
TECENTRIQ INTRAVENOUS SOLUTION 1,200 MG/20 ML (60 MG/ML), 840 MG/14 ML (60 MG/ML)	13, 14
TECFIDERA ORAL CAPSULE, DELAYED RELEASE (DR/EC) 120 MG, 120 MG (14)- 240 MG (46), 240 MG	151
TEFLARO	9, 10
TEMODAR INTRAVENOUS RECON SOLN 100 MG	190
temsirolimus intravenous recon soln 30 mg/3 ml (10 mg/ml) (first)	190
tencon oral tablet 50-325 mg	77
TERIPARATIDE	152, 153
tetrabenazine oral tablet 12.5 mg, 25 mg	178
THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG	154
thiotepa	13, 14
TIBSOVO	101
tigecycline	9, 10
tobramycin in 0.225 % nacl inhalation solution for nebulization 300 mg/5 ml	190
tobramycin sulfate	9, 10
topiramate oral capsule, sprinkle	158
topiramate oral tablet	158
toposar intravenous solution 20 mg/ml	190
topotecan intravenous solution 4 mg/4 ml (1 mg/ml)	190
TRAVASOL 10 % INTRAVENOUS PARENTERAL SOLUTION 10 %	190
TRAZIMERA	13, 14
TREANDA INTRAVENOUS RECON SOLN 100 MG, 25 MG	190
TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION	161
tretinoin microspheres	157
tretinoin topical	157
trientine	162
trihexyphenidyl	81
TRIPTODUR	65
TRODELVY INTRAVENOUS RECON SOLN 180 MG	190
TROKENDI XR	158
TROPHAMINE 10 % INTRAVENOUS PARENTERAL SOLUTION 10 %	190
TRUXIMA	13, 14
TUKYSA ORAL TABLET 150 MG, 50 MG	101
TURALIO	163
TYKERB	101
TYMLOS	164
TYSABRI	165, 166
TYVASO INHALATION SOLUTION FOR NEBULIZATION 1.74 MG/2.9 ML (0.6 MG/ML)	190
TYVASO INSTITUTIONAL START KIT INHALATION SOLUTION FOR NEBULIZATION 1.74 MG/2.9 ML	190
TYVASO REFILL KIT INHALATION SOLUTION FOR NEBULIZATION 1.74 MG/2.9 ML (0.6 MG/ML)	190

TYVASO STARTER KIT INHALATION SOLUTION FOR NEBULIZATION 1.74 MG/2.9 ML	190	XGEVA.....	179
U		XIAFLEX	180
UNITUXIN.....	13, 14	XIFAXAN ORAL TABLET 200 MG, 550 MG	181
UPTRAVI.....	167	XOLAIR SUBCUTANEOUS RECON SOLN	182, 183
V		XOLAIR SUBCUTANEOUS SYRINGE 150 MG/ML, 75 MG/0.5 ML	182, 183
valrubicin intravesical solution 40 mg/ml	190	XOPENEX CONCENTRATE INHALATION SOLUTION FOR NEBULIZATION 1.25 MG/0.5 ML ..	190
VALTOCO	168	XOPENEX INHALATION SOLUTION FOR NEBULIZATION 0.31 MG/3 ML, 0.63 MG/3 ML, 1.25 MG/3 ML	190
vancomycin oral capsule 125 mg, 250 mg	169	XOSPATA	101
VECTIBIX.....	13, 14	XPOVIO ORAL TABLET 100 MG/WEEK (20 MG X 5), 60 MG/WEEK (20 MG X 3), 80 MG/WEEK (20 MG X 4), 80MG TWICE WEEK (160 MG/WEEK).....	101
VELCADE.....	13, 14	XTANDI	101
VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG.....	101	XYREM	184
VENCLEXTA STARTING PACK	101	Y	
VENTAVIS.....	170	YERVOY INTRAVENOUS SOLUTION 200 MG/40 ML (5 MG/ML), 50 MG/10 ML (5 MG/ML)	13, 14
VERZENIO.....	171	YONDELIS.....	13, 14
VIBERZI.....	172	YUPELRI INHALATION SOLUTION FOR NEBULIZATION 175 MCG/3 ML	190
vinblastine intravenous solution 1 mg/ml	190	Z	
vincasar pfs intravenous solution 1 mg/ml, 2 mg/2 ml	190	ZALTRAP INTRAVENOUS SOLUTION 100 MG/4 ML (25 MG/ML), 200 MG/8 ML (25 MG/ML)	191
vincristine intravenous solution 1 mg/ml, 2 mg/2 ml	190	ZANOSAR INTRAVENOUS RECON SOLN 1 GRAM	191
vinorelbine intravenous solution 10 mg/ml, 50 mg/5 ml	190	ZEJULA.....	101
VITRAKVI ORAL CAPSULE 100 MG, 25 MG	173	ZELBORAF	101
VITRAKVI ORAL SOLUTION	173	ZIRABEV	13, 14
VIZIMPRO	101	ZOLADEX SUBCUTANEOUS IMPLANT 10.8 MG, 3.6 MG.....	191
voriconazole intravenous	11	zoledronic acid intravenous solution 4 mg/5 ml	191
VOSEVI.....	174	zoledronic acid-mannitol-water intravenous piggyback 4 mg/100 ml, 5 mg/100 ml	191
VOTRIENT.....	101		
VRAYLAR ORAL CAPSULE.....	19		
VRAYLAR ORAL CAPSULE,DOSE PACK.....	19		
VYXEOS INTRAVENOUS RECON SOLN 44-100 MG.....	190		
X			
XALKORI.....	101		
XATMEP	175		
XCOPRI.....	176		
XCOPRI MAINTENANCE PACK.....	176		
XCOPRI TITRATION PACK.....	176		
XELJANZ.....	177		
XELJANZ XR	177		

ZOLEDRONIC AC-MANNITOL-0.9NACL INTRAVENOUS PIGGYBACK 4 MG/100 ML	191	ZYDELIG	101
ZOLINZA	185	ZYKADIA ORAL TABLET	101
zonisamide	158	ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 210 MG, 300 MG, 405 MG.....	186
ZORTRESS ORAL TABLET 1 MG.....	84		